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ABSTRACT

Molecular Mechanisms of Chromium (VI) - Induced Apoptosis and
Malignant Transformation
NEELAM AZAD

Hexavalent chromium [Cr(VI)] compounds are redox cycling environmental carcinogens
that induce apoptosis as the primary mode of cell death. Apoptosis is abnormally regulated
in various disorders including cancer. Therefore, to understand the etiologies of these
diseases, it is important to delineate the biochemical and molecular pathways involved in
the regulation of apoptosis. The main objective of this study was to characterize the
molecular mechanisms involved in Cr(VI)-induced apoptosis and malignant
transformation. We found that both death receptor and mitochondrial pathways of
apoptosis are involved in Cr(VI)-induced apoptosis, with the latter being more dominant.
Consequently, overexpression of the mitochondrial anti-apoptotic protein Bcl-2 blocked
Cr(VI)-induced apoptosis in human lung epithelial cells. We further observed that reactive
oxygen species (ROS) play a critical role in Cr(VI)-induced apoptosis by acting through the
mitochondrial death pathway. Superoxide anion (·O2‾) was found to be the major ROS
involved in Cr(VI)-induced apoptosis that exerted its effect by degrading Bcl-2 protein
through the ubiquitin-proteasomal pathway. Furthermore, nitric oxide (NO) scavenged ·O2‾
to form peroxynitrite (ONOO‾) and negatively regulated Cr(VI)-induced apoptosis. The
mechanism by which NO exerted its anti-apoptotic effect involved upregulation of Bcl-2
via S-nitrosylation that prevented its ubiquitination and subsequent proteasomal
degradation. Additionally, we established an in vitro model for studying Cr(VI)-induced
malignant transformation by subjecting non-tumorigenic human lung epithelial Beas-2B
cell line to long-term Cr(VI) exposure. Cr(VI) transformed cells exhibited clear signs of
malignancy such as loss of contact inhibition and increased colony formation as compared
to the passage-matched original cell-line. Cr(VI) transformed cells showed decreased
apoptosis and ROS production and increased NO as well as Bcl-2 expression. These
observations confirmed that NO mediated stabilization of Bcl-2 is an important event in
Cr(VI) induced carcinogenesis. Taken together, our study reveals a novel regulatory
mechanism that could be important in apoptosis resistance in response to Cr(VI) exposure.
Additionally, this study demonstrated Cr(VI)-induced malignant transformation of a human
lung epithelial cell line, establishing an important in vitro model for studying the molecular
mechanisms involved in Cr(VI)-induced carcinogenesis. This study provides new
mechanistic insights about environmental carcinogen induced human lung cancer. Since
Cr(VI) is a paradigm of carcinogenic transition metals, the inferences from this study may
be broadly applied to general metal carcinogenesis.
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CHAPTER I
Background and Objective
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1.1. Chromium Exposure
Chromium (Cr) is a naturally occurring element found in rocks, animals, plants, soil,
volcanic dust, gases and living organisms (1, 2). Chromium commonly occurs in the
trivalent [Cr(III)] and hexavalent [(Cr(VI)] forms. Cr(III) compounds are normal dietary
constituents that affect sugar metabolism by potentiating insulin action via interaction with
the insulin receptor on the cell surface, and act as a cofactor in the maintenance of normal
lipid and carbohydrate metabolism (3-5). Cr(III) compounds are considered non-toxic, noncarcinogenic and non-mutagenic as they are poorly absorbed (6, 7). On the other hand,
Cr(VI) compounds are strongly associated with adverse health effects such as lung cancer.
Exposure to Cr(VI) has been associated with the induction of lung cancer in workers
employed in chrome plating, electroplating, leather tanneries, pigment manufacturing and
stainless steel welding (8-11). Non-occupational and environmental exposure to Cr occurs
from areas near landfills, chromate industries, hazardous waste disposal sites, automobile
emissions and cigarette smoke (1). In United States (US), increased incidence of lung
cancer has been reported in smokers with Cr(VI) exposure, with average cigarettes
containing 0.24/6.3 mg Cr/kg as estimated by the International Agency of Research on
Cancer (IARC) (9, 12). Cr(VI) compounds are classified as Group I human carcinogens by
IARC in 1990 (12). The carcinogenic potential of Cr(VI) depends upon various factors
such as water solubility, chemical speciation and involvement of reactive oxygen species
(ROS) (13). Although Cr(VI) does not interact with isolated DNA directly, it is
carcinogenic as it can actively enter cells, in contrast to Cr(III), by non-specific anionic
transport system (2). Inside the cell, it is metabolically reduced to its lower oxidation states.
These intermediates, specifically Cr(III), together with oxidative stress and a cascade of
cellular events are involved in Cr(VI)-induced toxicity and cell death (Fig. 1) (14). In the
cells, Cr(III) is the ultimate DNA binding species of Cr but Cr(III) compounds are
considered non-carcinogenic as they can not enter cells through the cell membrane
transporters (15). Cell death induced by Cr(VI) occurs primarily through apoptosis (16),
and its abnormal regulation has been associated with the initiation of Cr(VI)-induced
cancer(17). It has been suggested that Cr(VI) exposure may result in cell cycle arrest,
neoplastic transformation, and apoptosis induction (14, 18). However, the molecular
mechanisms involved in Cr(VI)-induced apoptosis and carcinogenesis are largely
unknown.
1.2. Apoptosis Signaling Cascades
Under normal conditions, cell cycle proceeds without interruptions. However, cell cycle
surveillance mechanisms sets checkpoints for cell cycle progression and if the cells are
damaged genetically or functionally, they undergo arrest in the G1 phase of the cell cycle
where the damaged cell is repaired before they enter the replication phase. Nevertheless, if
the cells are damaged beyond repair they undergo programmed cell death, i.e., apoptosis.
Apoptosis is a regulated physiological process leading to cell death characterized by cell
shrinkage, membrane blebbing and DNA fragmentation (19). Caspases, a family of
cysteine proteases, are central regulators of apoptosis. Initiator caspases such as caspase-8
and -9 activate downstream effector caspases and apoptosis (20, 21). Caspase-8 and -9 are
the key pro-apoptotic proteins of the two major pathways regulating apoptosis, viz., the
intrinsic pathway (mitochondria) and the extrinsic pathway (death receptor) (Fig. 2).
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1.2.1. Extrinsic pathway - This pathway of apoptosis is induced via signaling through a
family of death receptors including Fas (CD95/APO-1) and tumor necrosis factor receptor
- 1 (TNFR-1). Death receptor ligands characteristically initiate signaling by recruiting
specialized adaptor proteins to their cytosolic death domains resulting in the recruitment of
procaspase-8 to the death-inducing signaling complex (DISC) causing activation of
caspase-8 (22-24). Activated caspase-8 stimulates apoptosis via two parallel cascades 1) by
direct cleavage and activation of caspase-3 leading to apoptosis, and 2) by cleavage of Bid
(a Bcl-2 family protein) leading to apoptosis through the intrinsic pathway.
1.2.2. Intrinsic pathway - This pathway can be induced by pro-apoptotic Bcl-2 family of
proteins such as Bid, Bax and Bad that reside in the cytosol but translocate to the
mitochondria following death signaling. In the mitochondria they promote the release of
cytochrome c, which then binds to apoptotic protease activating factor 1 (Apaf 1) and
forms an activation complex (apoptosome) with procaspase-9 leading to its cleavage and
activation in the form of caspase-9 (25, 26). Caspase-9 activates effector caspases such as
caspase-3 leading to apoptosis. The mitochondrial pathway is also activated when cytosolic
Bid is cleaved by caspase-8 following signaling through the activation of death receptor
(27-29). Its active fragment or truncated Bid (tBid) translocates to the mitochondria,
inducing cytochrome c release, which sequentially activates caspases-9 and -3 leading to
cell death by apoptosis (Fig. 2).
1.3. Apoptosis Regulatory Proteins
The apoptotic pathways are regulated at different levels by various proteins including
FLICE-inhibitory protein (FLIP) and B-cell lymphoma-2 (Bcl-2). FLIP proteins are the
regulators of the extrinsic death receptor pathway. These anti-apoptotic proteins are
recruited to the DISC upon stimulation where they prevent procaspase-8 recruitment and
processing, preventing apoptosis through the extrinsic pathway (30-32). FLIP is involved in
rendering cells resistant to death receptor-mediated apoptosis in various cell types and
elevated expression of FLIP is associated with tumor cells that can escape from immune
surveillance in vivo (33-36). Bcl-2 is a key apoptosis-regulatory protein of the
mitochondrial death pathway (25). Formation of heterodimers with pro-apoptotic proteins
such as Bax, inhibition of cytochrome c release, and regulation of the mitochondrial
transmembrane potential are some of the mechanisms by which Bcl-2 exerts its antiapoptotic effect (37-39). The anti-apoptotic function of Bcl-2 is closely associated with its
expression levels, which is regulated by various mechanisms, including proteasomal
degradation. Selective modification of ε-NH2 groups of lysine residues in the protein ready
for degradation by ubiquitination is the initial step that targets the protein for degradation
by the proteasome complex (40, 41). Various factors such as specific structural features,
phosphorylation or a partially conserved sequence motif are implicated in making proteins
susceptible to degradation (42). However, the physiological signals that lead to protein
recognition by ubiquitin and degradation via the proteasomal pathway are unclear. The
importance of Bcl-2 and FLIP in the development of apoptosis resistant phenotype and
neoplastic development has been established. However, their role in Cr(VI)-induced
apoptosis and carcinogeneis is largely unknown.
1.4. Reactive oxygen species (ROS)
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ROS such as hydrogen peroxide (H2O2), superoxide anion (·O2‾), and hydroxyl radical
(·OH) are the byproducts of normal oxygen metabolism which participate in normal cell
functions and act as intracellular signaling molecules in many biological processes (43, 44).
However, excessive production of ROS may cause DNA damage and abnormal activation
of certain cell growth regulators, thereby leading to carcinogenesis (43). Mitochondria are
the primary but not the only source of ROS during apoptosis. The release of cytochrome c
in response to various apoptotic stimuli disrupts the mitochondrial electron transport chain
as cytochrome c is responsible for the transfer of electrons from complex III to IV (45).
This leads to the generation of ·O2‾ as a result of the leakage of electrons due to the
disruption of mitochondrial respiratory chain (45, 46). Cellular redox state plays a major
role in its response to external stimuli, induction or inhibition of apoptosis. Cr(VI)
compounds are redox cycling carcinogens that are reduced by certain flavoenzymes such as
glutathione reductase to generate Cr(V), Cr(IV) and Cr(III) in the cellular system (Fig. 1)
(17, 47-50). During this process, molecular oxygen is reduced to ·O2‾, which generates
H2O2 via dismutation. The resultant lower oxidation state intermediates react with H2O2
generating ·OH radical via a Haber-Weiss or Fenton like reaction (49) (Fig.1). Thus, during
the cellular reduction of Cr(VI), along with the reduced intermediates, a whole spectrum of
ROS are generated that cause diverse cytotoxic and genotoxic effects including DNA
damage, mutagenesis, growth arrest and cell death (51). Although various studies have
shown the involvement of ROS in Cr(VI)-induced apoptosis, its relationship with the well
studied caspase activation are not established.
1.5. Nitric oxide (NO)
NO is an important signaling molecule produced endogenously in a NADPH-dependent
reaction catalyzed by constitutively expressed or inducible NO synthases from the
guanodino group of L-arginine (52). There are 3 different genes encoding NO synthases
including 1) nNOS/NOS-1 (neuronal NOS) found in the neurons, 2) iNOS/NOS-2
(inducible NOS) found in macrophages, epithelial cells, T cells, endothelial cells and
eosinophils, and eNOS/NOS-3 (endothelial NOS) found in the endothelial cells lining the
lumen of blood vessels (53). The physiological levels of constitutively expressed NOS
remain relatively steady, whereas in response to an appropriate stimuli, iNOS catalyzes the
production of much higher levels of NO (53). NO is a multifunctional free radical that
diffuses freely across cell membranes and interacts with many other molecules. For
instance, it reacts rapidly with ·O2‾ in a diffusion controlled reaction to primarily form
peroxynitrite (ONOO¯) in most cell systems (54). ONOO¯ is a potent and versatile oxidant
that can attack a wide range of biological molecules. It is believed that the formation of
ONOO¯ anions due to the overproduction of NO is the main culprit in most of the diseases
related to NO. ONOO¯ plays a role in mediating cytotoxicity through alterations in protein,
lipids and nucleic acid structure and function with resultant disruption of cellular
homeostatic mechanisms leading to diseased conditions. The effects of ONOO¯ on protein
function are mainly due to its reactivity and covalent modification of tyrosine and/or
cysteine residues (55). One of the well-established mechanisms by which NO, through the
formation of ONOO¯, regulates the function of various target proteins is via S-nitrosylation
(56). This post-translational modification of proteins can positively or negatively regulate
various signaling pathways, proteins, and metabolic processes (57). Thus, NO exhibits
various physiological as well as pathophysiological effects. Subtle changes in its rate of
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production may critically impact cellular homeostasis, consequently initiating a variety of
cellular signaling processes, including apoptosis (58). Depending on a variety of factors,
including the flux and dose of NO, type of cells involved and redox state of the cell, NO
has been demonstrated to have both pro- and anti-apoptotic role (52). Even though NO has
been widely implicated in apoptosis and its dysregulation, its role in carcinogenesis is not
well characterized. In particular, the role of NO in Cr(VI)-induced apoptosis has never been
elucidated.
1.6. Cr(VI)-induced malignant transformation
Lung cancer is the leading cause of cancer mortality worldwide and yet the etiology of lung
cancer is poorly understood. Current research indicates that long-term exposure to inhaled
carcinogens has the greatest impact on risk of lung cancer. Exposure to Cr(VI) is associated
with the incidence of lung cancer in humans. Several epidemological studies in the last few
decades have associated exposure to Cr(VI) with the induction of lung cancer in workers in
various occupational settings (8-11). In US, a recent air quality survey indicated that people
in several residential areas are exposed to particulate airborne chromium at concentrations
exceeding 100 times the chronic toxicity benchmark (59). Therefore, in addition to
occupational exposure, environmental chromium is an emerging concern and is associated
with long-term carcinogenic effect of the lungs. However, these observations are not
supported by animal data. Several groups have established in various animal models that
exposure to Cr(VI) compounds demonstrated no significant increase in lung tumors as
compared to untreated control (60-62) and the reason for this discrepancy is not
understood. It is widely believed that human lung cancer manifests mostly as epithelial cell
derived carcinomas (14); however, it is still unknown whether human lung epithelial cells
are directly susceptible to Cr(VI)-induced malignant transformation. This is due to the lack
of a good model to study the molecular mechanisms of Cr(VI)-induced apoptosis and
malignant transformation. Abnormal apoptosis regulatory mechanisms and ROS generation
are considered as important factors in neoplastic development in response to Cr(VI).
However, the molecular mechanisms underlying Cr(VI)-induced apoptosis and malignant
transformation are poorly understood.
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FIGURE 1. Schematic representation of cellular reduction and cytotoxic effects of
Cr(VI).
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FIGURE 2. Diagrammatic illustration of the death receptor pathway and
mitochondrial pathway of apoptosis.
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1.7. SUMMARY
 Cr(VI) compounds are ubiquitous environmental carcinogens that primarily induce
cell death via apoptosis. Mitochondria-mediated intrinsic pathway and death
receptor-mediated extrinsic pathway are the two major signaling cascades of
apoptosis. However, the relative importance of these pathways in Cr(VI)-induced
apoptosis are largely unknown.
 Bcl-2 and FLIP are key regulatory proteins of the intrinsic and extrinsic pathways,
respectively. The relative importance of these apoptosis regulatory proteins in
response to Cr(VI) exposure is largely unknown. Since defects in apoptosis
regulatory mechanisms lead to neoplastic development, it is important to
understand the role of these key proteins in Cr(VI)-induced apoptosis.
 Activation of apoptosis is tightly linked with generation of ROS. ROS have been
implicated in the regulation of Cr(VI)-induced apoptosis and carcinogenicity.
However, the identity of specific ROS, precise source of ROS and the underlying
mechanism are largely unknown. The elucidation of the regulatory mechanisms of
apoptosis by ROS is crucial in understanding Cr(VI)-induced carcinogenesis.
 Exposure to Cr(VI) is associated with the incidence of lung cancer in humans.
Elevated levels of NO have been reported in human lung cancers (63-68). However,
the role of NO in Cr(VI)-induced apoptosis and malignant transformation has not
been elucidated.
 Lung cancers mostly manifests as epithelial cell derived carcinomas; however, it is
still unknown whether human lung epithelial cells are directly susceptible to
Cr(VI)-induced malignant transformation. This is due to the lack of a good model
system to study the molecular mechanisms involved in Cr(VI)-induced malignant
transformation.
1.8. SPECIFIC AIMS
The objective of this study was to characterize the molecular mechanisms of Cr(VI)induced apoptosis and malignant transformation. To achieve this goal we accomplished the
following specific aims:
Aim I: Delineate the signaling cascades and identify the key apoptosis-regulatory proteins
involved in Cr(VI)-induced apoptosis.
Aim II: Identify specific ROS, their cellular sources, and the mechanism by which ROS
regulates Cr(VI)-induced apoptosis.
Aim III: Study the role of NO in Cr(VI)-induced apoptosis and determine the underlying
mechanisms.
Aim IV: Establish a model to study Cr(VI)-induced malignant transformation and study
the mechanisms involved in the development of apoptosis resistant phenotype.
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CHAPTER II
Signaling Cascades Involved in Cr(VI)-Induced Apoptosis and
its Regulation by Reactive Oxygen Species
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2.1. Abstract
Cr(VI) compounds are redox cycling carcinogens that induce apoptotic cell death. Since
defects in apoptosis regulatory mechanisms contributes to increased resistance to apoptosis
induced by Cr(VI), it is critical to understand the molecular mechanisms involved in
Cr(VI)-induced apoptosis. Activation of apoptosis is tightly linked with the generation of
ROS. Likewise, ROS have been implicated in the regulation of Cr(VI)-induced apoptosis
and carcinogenicity. However, the mechanism involved, the identity of specific ROS and
the cellular source of ROS are largely unknown. The objective of this study was to
characterize the signaling pathways of Cr(VI)-induced apoptosis and evaluate the role of
ROS in this process. We observed that both extrinsic and intrinsic pathway are involved in
Cr(VI)-induced apoptosis and there is a potential cross-talk between the two pathways.
Further, it was found that the mitochondrial pathway is more dominant in response to
Cr(VI) exposure. Consequently, overexpression of the mitochondrial anti-apoptotic protein
Bcl-2 blocked Cr(VI)-induced apoptosis significantly as compared to Flip, which had
minimal effect. Recent evidences suggest that Bcl-2 protein inhibits apoptosis by
suppressing free radicals generation or by regulating cellular antioxidant defense
mechanisms. In this study, we also found that ROS, specifically superoxide (·O2‾),
mediates Cr(VI)-induced apoptosis of human lung epithelial H460 cells. ·O2‾ exerted its
effect by degrading Bcl-2 protein through the ubiquitin-proteasomal pathway. H460 ρ0
cells that lack mitochondrial DNA and a functional electron transport demonstrated a
significant decrease in ROS production and apoptosis indicating that mitochondria is the
major source of ROS in Cr(VI)-induced apoptosis of H460 cells. This study gives a
mechanistic understanding of ROS-mediated Bcl-2 downregulation and apoptosis induction
providing critical insight into the pro-oxidant role of Cr(VI) and the basis for differential
susceptibility to apoptotic cell death in response to Cr(VI) exposure.
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2.2. Introduction
Hexavalent chromium compounds are ubiquitous environmental carcinogens that have
been listed as Group I human carcinogens by IARC in 1990 (1). Exposure to Cr(VI) has
been associated with induction of lung cancer in various occupational settings (2-5). Nonoccupational exposure to Cr(VI) compounds occurs from cigarette smoke, automobile
emissions, areas of landfills and hazardous waste disposal sites (1, 3, 6). Cr(VI) has been
shown to induce chromosomal aberrations, mutations, and transformations in cultured
mammalian cells (7, 8), and a variety of DNA lesions such as strand breaks, DNA protein
cross-links, DNA base modification leading to cell death (9-12). Cell death induced by
Cr(VI) occurs primarily through apoptosis (13), and its abnormal regulation has been
associated with the initiation of Cr(VI)-induced cancer (14). Apoptosis is a tightly
regulated process characterized by shrinkage of the nucleus, blebbing of membranes,
condensation or fragmentation of chromatin that eliminates damaged cells maintaining
tissue homeostasis (15, 16). In general, two major pathways of apoptosis have been
recognized; the mitochondria-mediated intrinsic pathway and death receptor-mediated
extrinsic pathway. The extrinsic pathway of apoptosis is induced via signaling through a
family of death receptors such as Fas and TNFR-1, connecting ligand binding at the cell
surface to apoptosis induction (17-19). The intrinsic pathway is induced by pro-apoptotic
proteins belonging to the Bcl-2 family of proteins that reside in the cytosol but translocate
to the mitochondria following death stimuli and promote the release of cytochrome c
leading to apoptosis (20, 21). The mitochondrial pathway is also activated following
signaling through death receptor and caspase-8 that causes the cleavage, translocation and
activation of Bid, which sequentially activates caspases-9 and caspase-3 leading to
apoptosis (22-24). Therefore, there is a potential cross-talk between the two apoptotic
pathways. Both apoptotic pathways are regulated at different levels by various proteins
including Bcl-2 and FLIP. The anti-apoptotic protein FLIP is the key regulator of the
extrinsic pathway. It is recruited to the DISC upon stimulation where it prevents
procaspase-8 recruitment and processing (25-27). The anti-apoptotic protein Bcl-2 resides
in the outer mitochondrial wall and regulates apoptosis by controlling mitochondrial
permeability and the release of cytochrome c, thus, inhibiting apoptosis (20, 28, 29). Bcl-2
and Flip proteins are overexpressed in a variety of cancers and play a key role in these
malignancies. However, the role of Bcl-2 and FLIP in Cr(VI)-induced caspase activation
and apoptosis is largely unknown. Identifying the key mechanisms and apoptosis
regulatory proteins involved in Cr(VI)-induced apoptosis are critical in understanding the
development of apoptosis resistance phenotype in response to Cr(VI) exposure. However,
the detailed mechanism of apoptosis in response to Cr(VI) has not been systemically
investigated.
Several reports indicate that ROS can cause cell death via apoptosis (30, 31). ROS such as
hydrogen peroxide (H2O2), superoxide anion (·O2‾), and hydroxyl radical (·OH) are the
byproducts of normal oxygen metabolism which act as intracellular signaling molecules in
many biological processes (32, 33). However, excessive production of ROS may cause
DNA damage and abnormal activation of certain cell growth regulators, thereby leading to
carcinogenesis (32). Although recent evidences suggest that ROS have been implicated in
the regulation of Cr(VI)-induced apoptosis and carcinogenicity, the mechanisms of
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carcinogenesis are not yet clear (34-36). In the case of Cr(VI) compounds, cellular
reduction leads to the generation of ·O2‾ along with the formation of lower oxidation state
intermediates (14, 37, 38). ·O2‾ is further converted to H2O2 via dismutation, which reacts
with the resultant intermediates to generate ·OH radicals. ROS generated during the oneelectron reduction of Cr(VI) along with a cascade of cellular events causes diverse
cytotoxic and genotoxic effects including DNA damage, mutagenesis, growth arrest and
cell death (10). Programmed cell death or apoptosis can be modulated by the changes in the
expression of distinct sets of genes (15). The proto-oncogene Bcl-2 is one of the major
genes regulating apoptotic cell death. The anti-apoptotic function of Bcl-2 is regulated by it
expression levels. Various mechanisms including dimerization, phosphorylation,
degradation and post-translational modification regulate the stability and expression levels
of Bcl-2 protein (39, 40). Degradation of Bcl-2 is mainly mediated through the ubiquitinproteasomal pathway (39, 40). In vitro and in vivo studies suggest that Bcl-2 blocks
apoptosis through regulation of cellular antioxidant defense mechanisms or by suppressing
production of free radicals thus acting as an antioxidant (41-43). Even though ROS has
been implicated in Cr(VI)-induced apoptosis, the cellular source of ROS generation and its
relationship with the well-studied caspase activation has not been established.
The aim of this study was to delineate the signaling cascades involved in Cr(VI)-induced
apoptosis and evaluate the role of ROS in this process. We found that both extrinsic and
intrinsic pathway are involved in Cr(VI)-induced apoptosis and there is a potential crosstalk between the two pathways. Further, mitochondrial pathway of apoptosis was more
dominant in response to Cr(VI) and consequently, overexpression of Bcl-2 blocked Cr(VI)induced apoptosis significantly. Further, it was observed that generation of ROS induces
apoptotic cell death in response to Cr(VI) exposure and ·O2‾ is the major ROS involved in
Cr(VI)-induced apoptosis. Although, cytosolic ROS is involved, mitochondria is the major
cellular source of ROS involved in Cr(VI)-induced apoptosis. Further, it was observed that
·O2‾ mediated its pro-apoptotic effect by causing down-regulation and degradation of Bcl-2
through the ubiquitin-proteasomal pathway thus inducing apoptosis through the
mitochondrial pathway. The elucidation of the regulatory mechanisms of apoptosis by ROS
is crucial in understanding carcinogenesis induced by genotoxic agents such as chromium.
This study showing the role of ·O2‾ in Cr(VI)-induced cell death and Bcl-2 downregulation,
documents a novel mechanism of apoptosis induction by Cr(VI) involving Bcl-2 stability
linked to ·O2‾ generation. This study forms the basis of the mechanisms involved in the
development of apoptosis resistant phenotype in response to Cr(VI) and can be exploited
further to understand the molecular mechanisms involved in Cr(VI)-induced malignant
transformation and carcinogenic development.
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2.3. Materials and Methods
Chemicals and Reagents
N-acetyl cysteine (NAC), 6-Anilinoquinoline-5,8-quinone (LY-83,583), Hydrogen
peroxide (H2O2), Xanthine, Xanthine oxidase, rotenone, diphenylene iodonium (DPI),
lactacystin (LAC), ethidium bromide, sodium pyruvate, uridine and sodium dichromate
(Na2Cr2O7.2H2O) [Cr(VI)] were obtained from Sigma Chemical Inc. (St. Louis, MO).
Fluorogenic caspase substrates IETD amino-4-methylcoumarin (IETD-AMC), LEHDAMC, caspase-8 inhibitor (z-IETD-FMK), caspase-9 inhibitor (z-LEHD-FMK), pancaspase inhibitor (zVAD.FMK) and Flip antibody were from Alexis Biochemicals (San
Diego, CA). Cell-permeable superoxide dismutase (SOD) mimetic, Mn(III)tetrakis (4benzoic acid) porphyrin (MnTBAP), was purchased from Calbiochem (La Jolla, CA), and
catalase was from Boehringer Mannheim (Indianapolis, IN). The oxidative probes,
dichlorofluorescein diacetate (DCF-DA) and dihydroethidium bromide (DHE), and the
apoptosis dye Hoechst 33342 were from Molecular Probes (Eugene, OR). Antibodies for
caspase-8, caspase-9 and Bid were from Cell Signaling Technology, Inc. (Danvers, MA).
Antibodies for Bcl-2, peroxidase-labeled secondary antibodies, anti-myc agarose beads,
and protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
for ubiquitin, and β-actin were from Sigma (St. Louis, MO) and the transfecting agent
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).
Cell Culture
The human lung epithelial cancer NCI-H460 cell line was obtained from the American
Type Culture Collection (ATCC) (Rockville, MD). Cells were cultured in RPMI 1640
medium (Sigma, St. Louis, MO) containing 5% fetal bovine serum, 2 mM L-glutamine,
100 units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 environment at 37ºC.
Cells were passaged at preconfluent densities using a solution containing 0.05% trypsin and
0.5 mM EDTA (Invitrogen).
Caspase Assay
Caspase activity was determined by fluorometric assay using the enzyme substrate IETDAMC for caspase-8 and LEHD-AMC for caspase-9, which are specifically cleaved by the
respective enzymes at the Asp residue to release the fluorescent group, AMC. Cell extracts
containing 20 µg of protein were incubated with 100 mM HEPES containing 10% sucrose,
10 mM dithiothreitol, 0.1% 3-((3-cholamidiopropyl)-1) propane sulfonate, and 50 µM
caspase substrate in a total reaction volume of 0.25 ml. The reaction mixture was incubated
for 60 min at 37°C and quantified fluorometrically at the excitation and emission
wavelengths of 380 nm and 460 nm, respectively using RF5301PC spectro-fluorometer
(Shimadzu).
Apoptosis Assay
After specific treatments, apoptosis was determined by incubating cells with 10 µg/ml
Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the percentage of cells having
intensely condensed chromatin and/or fragmented nuclei by fluorescence microscopy
(Axiovert 100; Carl Zeiss) using Pixera software.
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Transient Transfection
H460 cells were seeded in 60-mm dishes until they reached 80% confluence. The cells
were then transiently transfected in serum free medium with the expression plasmids
encoding Flip or Bcl-2 and green fluorescent protein using Lipofectamine 2000 reagent.
After 10 h, the medium was replaced with culture medium containing 5% fetal bovine
serum. Approximately, 36 h after transfection, the cells were analyzed for apoptosis by
Hoechst assay.
Stable Transfection
Stable transfectants of Flip, Bcl-2, glutathione peroxidase (GPx) and superoxide dismutase
(SOD) were generated by culturing H460 cells in six-well plates until they reached 80%
confluence. 1 µg of cytomegalovirus-neo vector and 15 µl of Lipofectamine 2000 reagent
with 2 µg of Flip, Bcl-2, GPx, SOD, or control pcDNA3 plasmid were used to transfect the
cells in the absence of serum. After 10 h, the medium was replaced with culture medium
containing 5% fetal bovine serum. Approximately 36 h after the beginning of the
transfection, the cells were digested with 0.03% trypsin, and the cell suspensions were
plated onto 75 ml culture flasks and cultured for 24 to 28 days with G418 selection (400
µg/ml). Stable transfectants were identified by Western blot analysis and were cultured in
G418-free RPMI 1640 medium for at least two passages before each experiment.
ROS Detection
Intracellular peroxide and superoxide production was determined by flow cytometry and
fluorescence microscopy using DCF-DA and DHE fluorescence probes, respectively. For
flow cytometric analysis, cells (1x106/ml) were incubated with the fluoresecent probes (10
µM) for 30 min at 37ºC, after which they were washed, resuspended in phosphate buffered
saline (PBS), and analyzed for DCF (494/519 nm) and DHE fluorescence (535/617 nm)
using FACS calibur, (Becton-Dickinson, Rutherford, NJ). The median fluorescence
intensity was quantitated by CellQuest software (Becton-Dickinson) analysis of the
recorded histograms. For fluorescence microscopy, cells were incubated with the probes as
described above and then examined for DCF and DHE fluorescence using Carl Zeiss
Axiovert microscope.
Derivation of ρ0 cells
H460 ρ0 were prepared as previously described (44). Briefly, H460 cells were cultured in
the presence of ethidium bromide (100 ng/ml) to inhibit mitochondrial DNA replication for
more than 20 generations until use (ρ0 cells). ρ0 cells were derived and maintained in
complete medium supplemented with 100 µg/ml uridine and 100 µg/ml pyruvate.
Western Blotting
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF,
100 mM phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor mixture for 20 min
on ice. After insoluble debris was precipitated by centrifugation at 14,000 x g for 15 min at
4°C, the supernatants were collected and assayed for protein content using bicinchoninic
acid (BCA) method. Equal amount of proteins per sample (15 µg) were resolved on 10%
SDS-PAGE and transferred onto a 0.45-µm nitrocellulose membrane. The transferred
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membranes were blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl, pH
7.4, 125 mM NaCl, 0.05% Tween 20) and incubated with the appropriate primary
antibodies and horseradish peroxidase-conjugated secondary antibodies. The immune
complexes were detected by chemiluminescence (Supersignal, West Pico; Pierce) and
quantified by imaging densitometry using UN-SCAN-IT automated digitizing software
(Silk Scientific Corp.). Mean densitometry data from independent experiments were
normalized to the control. The data were presented as mean ± S.D. and analyzed by
Student’s t test.
Immunoprecipitation
Stable H460 cells overexpressing Bcl-2 were washed after treatments with ice-cold PBS
and lysed in lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 10% glycerol, 0.2% NP40,
100 mM PMSF and a commercial protease inhibitor mixture) at 4°C for 20 min. After
centrifugation at 14,000 x g for 15 min at 4oC, the supernatants were collected and the
protein content was determined by BCA protein assay. Cleared lysates were normalized
and 60 µg proteins were incubated with 8 µl of anti-myc agarose bead (Santa Cruz
Biotechnology) diluted with 12 µl protein A-agarose for 4 h at 4oC. The immune
complexes were washed 3 times with 500 µl lysis buffer, resuspended in 2x Laemmli
sample buffer and boiled at 95oC for 5 min. The immune complexes were separated by
10% SDS-PAGE and analyzed by Western blot as described above.
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2.4. Results
Cr(VI) Induced Cell Death – Cr(VI)-containing compounds are ubiquitous environmental
carcinogens that induce apoptosis as the primary mode of cell death (13). To characterize
the signaling pathways involved in Cr(VI)-induced apoptosis, we first characterized the
apoptotic response to Cr(VI) treatment in human lung epithelial H460 cells. Cells were
treated with different doses of Cr(VI) (0-100 µM), and apoptosis was determined after 12 h
by Hoechst 33342 assay. Figs. 1, A and B, show that Cr(VI) treatment caused a dosedependent increase in cell apoptosis over control level, as indicated by increased nuclear
fluorescence and chromatin condensation of the treated cells. Cells were also treated with
zVAD, a pan-caspase inhibitor, in addition to Cr(VI). Figs. 1, C and D, show that zVAD
treatment blocked Cr(VI)-induced apoptosis, reducing it to control levels. This indicated
that Cr(VI) induces apoptosis through the classical caspase dependent pathways.
Signaling Pathways Induced by Cr(VI) – Various studies have demonstrated that caspase-8
and caspase-9 represent the apical caspases in the death receptor and mitochondrial
pathways, respectively (45-48). Therefore, to investigate the potential involvement of the
extrinsic and intrinsic pathway in Cr(VI)-induced apoptosis, cleavage and activation of
caspase-8 and caspase-9 in response to Cr(VI) exposure was analyzed by Western blotting
and caspase activation assays. Western blot analysis showed that both apoptotic pathways
were activated in response to Cr(VI) (Figs. 2, A and B). Additionally, we also observed that
Bid protein was cleaved and activated (tBid) in response to Cr(VI), suggesting a potential
cross-talk between the two apoptotic pathways. Since caspase activation leads to the
activation of Bid, this indicates that H460 cells are Type II cells (Fig. 2C).
Caspase Activation Induced in Response to Cr(VI) Exposure – Caspase activity assays
confirmed that Cr(VI) induced both caspase-8 and caspase-9 activation. Furthermore, it
demonstrated that the mitochondrial pathway is more dominant in response to Cr(VI)
exposure (Fig. 3A). Since caspase-8 and caspase-9 are the key marker proteins of the death
receptor pathway and mitochondrial pathway, the results of this study suggest that the
mitochondrial pathway is the major apoptotic pathway induced in response to Cr(VI)
exposure. Control studies using specific caspase-8 inhibitor (IETD-CHO) and caspase-9
inhibitor (LEHD-CHO) indicate the specificity of caspase activation under the test
conditions (Fig. 3B). It was also observed that both caspase inhibitors reduced apoptosis to
the control levels further confirming the involvement of caspases in Cr(VI)-induced
apoptosis (Fig. 3C).
Effect of Cr(VI) on Apoptosis Regulatory Proteins – Bcl-2 is the key apoptosis-regulatory
protein of the mitochondrial death pathway and FLIP is the key protein of the death
receptor pathway (20, 25-29). To determine the effect of Cr(VI) exposure on these proteins,
cells were treated with various doses of Cr(VI) and analyzed for Flip and Bcl-2 expression
by immunoblotting. Both, Flip and Bcl-2 protein levels were downregulated in response to
Cr(VI) exposure (Figs. 4, A and B). To determine whether these proteins are involved in the
regulation of Cr(VI)-induced apoptosis, H460 cells were transiently transfected with Flip,
Bcl-2 or control plasmid, and their effect on Cr(VI)-induced apoptosis was determined by
Hoechst 33342 assay. Fig. 4C shows that transfection with both Flip and Bcl-2 inhibited
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Cr(VI)-induced apoptosis as compared with the vector-transfected control, with the effect
of Bcl-2 being more pronounced as compared to the effect of Flip.
Bcl-2 Overexpression Protects Cells from Cr(VI)-Induced Apoptosis – To further verify the
effect observed after transient transfection of Flip and Bcl-2 proteins. Stable H460 celllines overexpressing Flip and Bcl-2 proteins were established and overexpression was
confirmed by Western blot analysis. Transfected cells showed an increase in Bcl-2 and Flip
protein expression in the Bcl-2-transfected cells and Flip-transfected cells but not in the
control transfectant (Figs. 5, C and D). Further, stably transfected H460 cells with Flip,
Bcl-2 or control plasmid, were tested for their effect on Cr(VI)-induced apoptosis by
Hoechst 33342 assay. Overexpression of Bcl-2 significantly inhibited Cr(VI)-induced
apoptosis over a wide concentration range as compared to the vector-transfected control
(Fig. 5A), whereas Flip overexpression had minimal effect (Fig. 5B). These results indicate
the role of Bcl-2 as a negative regulator of Cr(VI)-induced apoptosis and further suggest
that H460 cells are Type II cells, supporting the role of the mitochondrial pathway in
Cr(VI)-induced cell death.
Effect of Cr(VI) and ROS Modulators on Cellular ROS Levels – In the cellular system,
Cr(VI) is metabolically reduced to its lower oxidation states, generating ROS in this
process (14, 37, 38). Therefore, we quantified the induction of cellular ROS production in
response to Cr(VI) exposure by flow cytometry in treated cells using the fluorescent
probes DCF and DHE, which detect hydroperoxide and ·O2‾, respectively. Cr(VI) induced
hydroperoxide and ·O2‾ production in a dose-dependent manner, as indicated by the
increase in DCF and DHE fluorescence intensity (Figs. 6, A-C). Various ROS modulators
used in combination with Cr(VI) verified these results. DHE signal was increased by
Cr(VI) and LY-83,583 (·O2‾ donor) and was inhibited by the addition of the SOD mimetic
MnTBAP (·O2‾ scavenger) and the general antioxidant NAC (Fig. 7, A and F). Similarly,
DCF signal was increased by Cr(VI) and H2O2 and was inhibited by NAC and catalase (
H2O2 scavenger) (Fig. 7, B and C).
ROS Mediated Cr(VI) Induced Apoptosis – Apoptosis is strongly linked with ROS
induction. To test whether the apoptosis-inducing effect of Cr(VI) is associated with ROS
production, cells were treated with Cr(VI) in the presence or absence of various ROS
modulators, including NAC, catalase, MnTBAP, and xanthine/xanthine oxidase (·O2‾
donor), and apoptosis was determined by Hoechst assay. The results show that all the tested
antioxidants were able to inhibit apoptosis induced by Cr(VI) (Fig. 8, A and B), indicating
that multiple ROS are involved in the apoptotic process. The potent inhibitory effects of
catalase and MnTBAP further indicate that H2O2 and ·O2‾ play an important role in the
process.
GPx and SOD Overexpression Inhibits Cr(VI)-Induced Apoptosis and ROS Generation To confirm the role of ROS in Cr(VI)-induced apoptosis, cells were stably transfected with
the antioxidant enzymes GPx, SOD, or control plasmid, and their effects on ROS
generation and apoptosis were determined. Apoptosis assays showed a decrease in
apoptotic response to Cr(VI) treatment in GPx- and SOD-transfected cells but not in mocktransfected cells (Fig. 9, A and B). Flow cytometric analysis of hydroperoxide generation
and ·O2‾ also showed a substantial reduction in Cr(VI)-induced fluorescence in both GPx22

and SOD-transfected cells as compared with mock-transfected cells (Fig. 9, C and D). It
was observed that SOD overexpressed cells showed more significant decrease in ROS and
apoptosis induction. In SOD overexpressed cells, apoptosis did not change significantly
even with 100 µM Cr(VI). This indicated significant involvement of ·O2‾ anion in Cr(VI)induced apoptosis.
Mitochondrial ROS are Responsible for Cr(VI)-Induced Apoptosis – To determine the
cellular source of ROS involved in Cr(VI)-induced apoptosis, cells were treated with
Cr(VI) in the presence or absence of DPI, a specific inhibitor of NADPH oxidase (49, 50),
or rotenone, a mitochondrial electron transport chain interrupter (50, 51), and their effects
on apoptosis and ROS generation were examined. The results show that both DPI and
rotenone inhibited Cr(VI)-induced ROS generation and apoptosis, with the effect of
rotenone being more pronounced (Fig. 10, A-D). These results indicate that even though
cytosolic ROS may be involved, mitochondria is the major source of ROS involved in
Cr(VI)-induced apoptosis. The differential inhibitory effect of rotenone on ·O2‾ and
peroxide generation could reflect the non-specific effect of this compound on ROS and the
varying rates of reaction between the ROS, their probes, and the compound. The role of
specific ROS in Cr(VI)-induced apoptosis could be more conclusively addressed using
specific ROS modulators, as shown earlier.
Cr(VI)-Induced ROS and Apoptosis is Reduced in H460 ρ0 Cells – Mitochondria is an
important source of ROS that generates oxidative stress by incomplete reduction of oxygen
from the electrons that escape normal oxidative phosphorylation (52). To confirm the role
of mitochondrial ROS in Cr(VI)-induced apoptosis, we compared Cr(VI)-induced ROS
formation in H460 and H460 ρ0 cells as assessed by DHE and DCF fluorescence. It was
observed that Cr(VI)-induced ·O2‾ and ROS production in H460 cells was decreased
significantly in H460 ρ0 cells (Figs. 11, A and B). Further, it was observed that Cr(VI)induced apoptosis was reduced by half in H460 ρ0 cells as compared to H460 cells
indicating that mitochondrial functional electron transport is important for mediating
Cr(VI)-induced apoptosis (Fig. 11C).
Effect of Cr(VI) on Bcl-2 Expression – To provide mechanistic insight into the regulation of
Cr(VI)-induced apoptosis by Bcl-2, the expression level of Bcl-2 in response to Cr(VI)
treatment was determined by Western blot analysis. Having demonstrated the role of Bcl-2
in Cr(VI)-induced apoptosis, the effect of Cr(VI) treatment on Bcl-2 expression was
characterized in these cells by immunoblotting. Fig. 12A shows that treatment of the cells
with Cr(VI) caused a dose-dependent decrease in the expression level of Bcl-2. Fig. 12B
shows that this effect of Cr(VI) was time-dependent with the effect clearly noticeable at 6 h
post-treatment and thereafter.
Effect of Antioxidants on Bcl-2 Expression – Having shown the role of Bcl-2 in Cr(VI)induced apoptosis, we next investigated the potential regulation of Bcl-2 by ROS. ROS
have previously been shown to mediate tumor necrosis factor-induced proteasomal
degradation of Bcl-2 in human umbilical vein endothelial cells (39). To test whether ROS
might also mediate the effect of Cr(VI) on Bcl-2, cells were treated with Cr(VI) in the
presence or absence of ROS modulators, and their effect on Bcl-2 expression was
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determined. Figure 13A shows that treatment of the cells with MnTBAP completely
inhibited Cr(VI)-induced Bcl-2 down-regulation, whereas catalase treatment showed no
inhibitory effect suggesting an important role of ·O2‾ in Bcl-2 degradation. These results
were confirmed in GPx- and SOD-overexpressed cells. Figure 13B shows that SOD
overexpression completely inhibited Cr(VI)-induced Bcl-2 down-regulation, whereas GPx
overexpression was ineffective. These results indicate that ·O2‾ is the primary ROS
responsible for Cr(VI)-induced Bcl-2 down-regulation. Furthermore, the expression of Bcl2 was upregulated in H460 ρ0 cells suggesting that mitochondrial ·O2‾ is important in Bcl-2
degradation (Fig. 13C). This is consistent with our earlier observation that mitochondrial
·O2‾ is the major regulator of Cr(VI)-induced apoptosis.
ROS Mediates Cr(VI)-Induced Ubiquitination of Bcl-2 - Previous studies have shown that
Bcl-2 is down-regulated primarily through the proteasomal degradation pathway (39, 53),
we tested whether such degradation is involved in the down-regulation of Bcl-2 by Cr(VI).
Cells were treated with Cr(VI) in the presence or absence of lactacystin (LAC), a highly
specific proteasome inhibitor, and its effect on Bcl-2 expression was determined. Figure
14A shows that LAC completely inhibited Bcl-2 down-regulation induced by Cr(VI). This
finding indicates that proteasomal degradation is a key mechanism of Cr(VI)-induced Bcl-2
down-regulation. To further investigate the mechanism by which ROS mediates Cr(VI)induced Bcl-2 degradation, we analyzed ubiquitination of Bcl-2 in response to Cr(VI)
treatment by immunoprecipitation. Cells overexpressing myc-Bcl-2 were treated with
Cr(VI) in the presence or absence of ROS donors and inhibitors. Cell lysates were prepared
and immunoprecipitated using anti-myc antibody. The resulting immune complexes were
analyzed for ubiquitination by Western blot using anti-ubiquitin antibody. The results show
that Cr(VI) was able to induce ubiquitination of Bcl-2 and the ·O2‾ donor LY-83,583
increased this effect (Fig. 14B). In contrast, ·O2‾ scavenger MnTBAP inhibited Bcl-2
ubiquitination, suggesting that ·O2‾ is the major ROS involved in Cr(VI) induced Bcl-2
degradation. H2O2 donor and inhibitor had minimal effect. This result supported the proapoptotic role of ROS in ubiquitin-mediated degradation of Bcl-2 by Cr(VI) and
established a novel mechanism linking ·O2‾ signaling with Bcl-2 stability.
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2.5. Discussion
Cr(VI) is a known human carcinogen that has been associated with lung cancer (3). Since
acquired resistance to genotoxic cell death is a hallmark of neoplastic progression, it is
important to understand the molecular mechanisms by which cells acquire an apoptosis
resistant phenotype in response to genotoxic insult such as exposure to Cr(VI). Therefore,
we first characterized the apoptotic pathways and regulatory proteins involved in Cr(VI)induced apoptosis. In this study, we demonstrated that Cr(VI) induces apoptosis in a dose
dependent manner and zVAD completely blocked this effect (Fig.1). Since zVAD is a
general caspase inhibitor, this result indicated that Cr(VI) induces apoptosis via classical
caspase dependent manner. Apoptosis may be initiated through the stimulation of death
receptors located on the cell surface or through the intrinsic pathway involving the release
of apoptotic signals from mitochondria. To gain a mechanistic understanding of the
susceptibility to cell death in response to Cr(VI) exposure, we further showed that both
mitochondrial and death receptor pathways of apoptosis were activated by Cr(VI) (Fig. 2, A
and B). There have been studies suggesting a potential cross-talk between the two
pathways in many cell-types. In the so called ‘Type I” cells, stimulation of death receptors
has been reported to cause caspase-8 mediated cleavage and activation of caspase-3 (54,
55). This pathway does not require mitochondria-associated events, whereas in “Type II’
cells caspase-8 leads to the cleavage and activation of Bid protein (56-58). Truncated bid
stimulates formation of Bax pores in the outer mitochondrial membrane, which mediates
the release of cytochrome c and, consequently, formation of Apaf-1/caspase-9 apoptosome
(59). We observed that there is a potential cross-talk between the two apoptotic pathways in
response to Cr(VI) exposure in H460 cells (Fig. 2C). Bid cleavage also suggested that
H460 cells are Type II cells. Spectrofluorometric analysis further confirmed that both
apoptotic pathways are induced by Cr(VI) exposure, with the mitochondrial pathway
playing a more dominant role as compared to the death receptor pathway (Fig. 3, A and B).
This observation was in agreement with another report that suggested that apoptotic doses
of Cr(VI) caused mitochondrial instability (60). Various pro- and anti-apoptotic proteins
regulate the extrinsic and intrinsic pathways. Interestingly, induction of pro-apoptotic
proteins does not necessarily lead to apoptosis induction (26, 27), indicating that inhibitors
of both apoptotic pathways exist and are important. Flip is the negative regulator of the
death receptor pathway (25, 61, 62) while Bcl-2 plays a key role in the mitochondrial
pathway (20, 28, 29). We observed that Cr(VI) downregulated both FLIP and Bcl-2 in a
dose dependent manner (Fig. 4, A and B). It was observed that Bcl-2 overexpression
strongly blocked Cr(VI)-induced apoptosis, whereas Flip had minimal effect (Fig. 4C and
5, A and C). This further substantiated the role of the mitochondrial death pathway in
Cr(VI)-induced apoptosis.
Cr(VI) is actively transported into cells by anionic transport system at the cellular level (64)
and is metabolically changed to the ultimate reduced form, Cr(III), in a process that also
produced ROS. Since generation of ROS is a definite consequence of Cr(VI) exposure we
also demonstrated the role of ROS in Cr(VI)-induced apoptosis of human lung cancer
epithelial H460 cells. Consistent with the observation that reduction of Cr(VI) inside the
cell produces ROS, our results showed that Cr(VI) was able to induce ·O2‾ and peroxide
generation in human lung epithelial H460 cells (Fig. 6 and 7). We also observed that ROS
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was responsible for Cr(VI)-induced apoptosis (Fig. 8). This was verified in the presence of
antioxidants such as NAC, catalase, and MnTBAP that effectively inhibited apoptosis
induced by Cr(VI), indicating the role of ROS, specifically ·O2‾ and H2O2, in this process.
H460 cells overexpressing GPx and SOD showed reduced apoptotic responses to Cr(VI)
treatment (Fig. 9, A and B). This effect was more pronounced in SOD-overexpressed cells
suggesting that even though both ·O2‾ and H2O2 are important, ·O2‾ is the major ROS
involved in Cr(VI) apoptosis. To determine the source of ROS involved in Cr(VI)-induced
apoptosis, we utilized DPI and rotenone. Rotenone has previously been shown to inhibit
mitochondrial ROS and DPI is known to inhibit cellular NADPH oxidase and are
considered as indicators of the mitochondrial and cytosolic ROS, respectively (49-51).
Cr(VI) induced ROS generation and apoptosis was significantly inhibited by DPI and
rotenone, with the effect of the latter being more dominant (Fig. 10). This indicated that
total ROS produced in the cell is important in Cr(VI) induced apoptosis, but mitochondrial
ROS plays a major role. This was further confirmed in H460 ρ0 cells which are prepared by
long-term exposure to ethidium bromide that leads to the depletion of critical respiratory
chain sub-units encoded by mitochondrial DNA (65, 66). Therefore these cells are
incapable of generating mitochondrial ROS and normal oxidative phosphorylation (67).
We observed decreased ROS production and apoptosis in H460 ρ0 as compared to H460
cells (Fig. 11). Since ρ0 cells have dysfunctional mitochondria, this observation indicated
an important role of mitochondrial electron transport chain and ROS in Cr(VI) induced
apoptosis (68, 69).
Since we observed that the anti-apoptotic protein Bcl-2 overexpression plays a key role in
Cr(VI)-induced apoptosis, we tested the effect of Cr(VI) on Bcl-2 expression. Exposure of
the cells to Cr(VI) caused a dose- and time-dependent down-regulation of Bcl-2 (Fig. 12, A
and B). We found that this down-regulation was ROS dependent as co-treatment of the
cells with the ·O2‾ scavenger MnTBAP completely inhibited the down-regulation of Bcl-2
by Cr(VI) (Fig. 13A). H2O2 scavenger catalase failed to inhibit this effect, indicating that
H2O2 has a minimal role in Cr(VI)-induced Bcl-2 down-regulation and apoptosis. Gene
transfection studies using GPx- and SOD-overexpressed cells confirmed these results and
indicated the critical role of ·O2‾ in this process (Fig. 13B). The observation that catalase
and GPx failed to inhibit Bcl-2 down-regulation while exhibiting a protective effect on
Cr(VI)-induced apoptosis suggests that other peroxide-mediated Bcl-2-independent
mechanisms may be involved in the apoptotic effect of Cr(VI). It was further observed that
H460 ρ0 cells inhibited Bcl-2 down-regulation when treated with Cr(VI) as compared to
H460 cells(Fig. 13C). This suggested that mitochondrial ·O2‾ plays a critical role in
maintaining Bcl-2 stability. The anti-apoptotic function of Bcl-2 is closely associated with
its expression levels, which is controlled by various mechanisms. Post-translational
modifications, such as ubiquitination and phosphorylation, have emerged as important
regulators of Bcl-2 function (39, 40, 70). The ability of the proteasome inhibitor lactacystin
to inhibit Bcl-2 down-regulation strongly supports the role of the proteasomal pathway in
Bcl-2 regulation (Fig. 14A). We observed that ·O2‾ scavenger MnTBAP inhibited Bcl-2
ubiquitination induced by Cr(VI), whereas ·O2‾ donor LY-83,583 promoted this effect (Fig.
14B). H2O2 modulators had minimal effect. These results indicate that ·O2‾ downregulates
Bcl-2 by inducing its degradation via the ubiquitin-proteasomal pathway in response to
Cr(VI) exposure.
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In summary, our data provides evidence that apoptosis induced by Cr(VI) is mediated
through the mitochondrion-dependent caspase-9 activation pathway, which is negatively
regulated by the anti-apoptotic Bcl-2 protein. ROS plays an important role in Cr(VI)induced apoptosis of human lung cancer epithelial H460 cells. The mechanism by which
Cr(VI) induces apoptosis involves rapid generation of ROS and ·O2‾ is the major ROS
involved. Mitochondria is the main source of ROS that is involved in Cr(VI)-induced
apoptosis. Cr(VI) induces down-regulation of Bcl-2 through a process that involves ·O2‾mediated proteasomal degradation of the protein. Exposure to Cr(VI) is associated with
lung cancer and Bcl-2 has been shown to be overexpressed in various cancers including
lung tumor cells and tissue specimen (71-73). This aim established the importance of
mitochondrial pathway and Bcl-2 protein in Cr(VI)-induced apoptosis which will further
help in understanding the carcinogenicity of Cr(VI). ·O2‾ may represent a common
regulator of Bcl-2 function that controls apoptotic cell death induced by various
physiologic and pathologic stimuli. This study showing the role of ·O2‾ in Cr(VI)-induced
cell death and Bcl-2 downregulation, documents a novel mechanism of apoptosis induction
by Cr(VI) involving Bcl-2 stability linked to ·O2‾ generation. Signal transduction leading to
apoptotic cell death has been of great interest in biomedical and pharmaceutical research
mainly because successful apoptotic agents could be used to treat cancer.
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FIGURE 1. Induction of apoptosis by Cr(VI) in human lung epithelial H460 cells. A,
subconfluent (90%) monolayers of H460 cells were exposed to varying doses of Cr(VI) (0100 µM) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342 assay. C,
subconfluent (90%) monolayer of H460 cells were exposed to zVAD (25 µM) for 1 h and
were then treated with Cr(VI) (20 µM) for 12 h, and the cells were analyzed for apoptosis
by Hoechst 33342 assay. B and D, fluorescence micrographs of treated cells stained with
Hoechst dye. Apoptotic cells exhibited shrunken and fragmented nuclei with bright nuclear
fluorescence. Values are mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control.
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FIGURE 2. Signaling Cascades Induced by Cr(VI). H460 cells were treated with varying
doses of Cr(VI) (10, 20, 50 µM) for 12 h, and cell lysates were prepared and analyzed for
A, Caspase-8, B, Caspase-9 and C, Bid expression by Western blotting.
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FIGURE 3. Caspase activation in response to Cr(VI) exposure. A, fluorometric assay of
caspase activity in cells treated with varying doses of Cr(VI) (1-50 µM) for 12 h. Cell
lysates (50 µg of protein) were prepared and analyzed for caspase activity using the
fluorometric substrates IETD-AMC and LEHD-AMC for caspase-8 and -9, respectively. B,
fluorometric assay of caspase activity in cells treated with Cr(VI) (20 µM) for 12 h in the
presence or absence of the caspase-8 inhibitor IETD-CHO (10 µM) or caspase-9 inhibitor
LEHD-CHO (10 µM). C, Apoptosis assay of caspase activity in cells treated with Cr(VI)
(20 µM) for 12 h in the presence or absence of the caspase-8 inhibitor IETD-CHO (10 µM)
or caspase-9 inhibitor LEHD-CHO (10 µM). Values are mean ± S.D. (n > 3). *, p < 0.05
versus non-treated control.
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FIGURE 4. Effect of Cr(VI) on apoptosis regulatory proteins. H460 cells were treated
with varying doses of Cr(VI) (10, 20, 50 µM) for 12 h, and cell lysates were prepared and
analyzed for A, Bcl-2 and B, Flip expression by Western blotting. Blots were reprobed with
β-actin antibody to confirm equal loading of samples. C, H460 cells were transiently
transfected with myc-tagged Bcl-2 plasmid, myc-tagged Flip plasmid or control pcDNA3
plasmid. Transfected cells were treated with Cr(VI) (10 and 20 µM) for 12 h and apoptosis
was determined by Hoechst 33342 assay. Values are mean ± S.D. (n > 3).
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FIGURE 5. Bcl-2 overexpression increases cell death resistance to Cr(VI). A and B,
H460 cells were stably transfected with myc-tagged Bcl-2 plasmid, myc-tagged Flip
plasmid or control pcDNA3 plasmid. Transfected cells were treated with varying doses of
Cr(VI) (0-100 µM) for 12 h and apoptosis was determined by Hoechst 33342 assay. Plots
are mean ± S.D. (n = 4). *, p < 0.05 versus mock-transfected controls. C, Western blot
analysis of Bcl-2 expression in mock- and Bcl-2-transfected cells. D, Western blot analysis
of Flip expression in mock- and Flip-transfected cells. β-Actin was used as a loading
control.
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FIGURE 6. Effect of Cr(VI) on cellular ROS levels. A, B and C, subconfluent (90%)
monolayers of H460 cells were treated with varying doses of Cr(VI) (0-100 µM) and
analyzed for ·O2‾ and peroxide production by flow cytometry using DHE and DCF
fluorescent probes.
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FIGURE 7. Effect of ROS modulators on cellular ROS levels. A and B, subconfluent
(90%) monolayers of H460 cells were pretreated with NAC (10 mM), MnTBAP (100 µM)
or catalase (10000 U/ml) for 0.5 h, followed by Cr(VI) (20 µM) treatment. Plots show
relative DHE or DCF fluorescence intensity over non-treated control determined at the
peak response time of 1 h after Cr(VI) treatment. LY-83,583 (10 µM) and H2O2 (0.1 mM)
were used as positive controls for DHE and DCF, respectively. C, Fluorescence
micrographs of treated cells from above. Values are mean ± S.D. (n > 3). *, p < 0.05 versus
non-treated control.
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FIGURE 8. Induction of apoptosis by ROS modulators in H460 cells. A, subconfluent
(90%) monolayers of H460 cells were either left untreated or pretreated with NAC (10
mM), MnTBAP (100 µM), catalase (10000 U/ml) or xanthine/xanthine oxidase (1 mM/
0.02 U) for 1 h. The cells were then treated with Cr(VI) (20 µM) for 12 h and analyzed for
apoptosis by Hoechst assay. B, Fluorescence micrographs of treated cells stained with
Hoechst 33342 dye. Values are mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control.
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FIGURE 9. Effect of GPx and SOD overexpression on Cr(VI)-induced apoptosis and
ROS generation. A and B, H460 cells were stably transfected with GPx, SOD, or control
pcDNA3 plasmid as described under Materials and Methods. Transfected cells were
treated with Cr(VI) (1-100 µM) for 12 h and analyzed for apoptosis by Hoechst 33342
assay. C and D, transfected cells were treated with Cr(VI) (1-100 µM) and analyzed for
DCF and DHE fluorescence intensities at 1 h post-treatment. Plots show relative
fluorescence intensity over non-treated control. Values are mean ± S.D. (n > 3).
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FIGURE 10. Cellular source of Cr(VI)-induced ROS. A and B, Cells were pretreated for
0.5 h with DPI (5 µM) or rotenone (5 µM), followed by Cr(VI) treatment (20 µM) and
were analyzed for DHE and DCF fluorescence intensities at 1 h post-treatment. C, H460
cells were either left untreated or pretreated with the indicated concentrations of DPI or
rotenone for 1 h. Cells were then treated with Cr(VI) (20 µM) and analyzed for apoptosis
after 12 h. D, fluorescence micrographs of treated cells stained with Hoechst 33342 dye.
Values are mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control.
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FIGURE 11. Cr(VI)-induced ROS and apoptosis is reduced in H460 ρ 0 cells. A and B,
H460 and H460 ρ0 cells were treated with Cr(VI) (10, 20 and 50 µM) for 1 h and analyzed
for DHE and DCF fluorescence intensities. Plots show relative fluorescence intensity over
non-treated control. C, subconfluent (90%) monolayers of H460 cells and H460 ρ0 cells
were treated with varying doses of Cr(VI) (0-100 µM) for 12 h, and the cells were analyzed
for apoptosis by Hoechst 33342 assay. Values are mean ± S.D. (n > 3). *, p < 0.05 versus
non-treated control.
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FIGURE 12. Effect of Cr(VI) on Bcl-2 expression. A, H460 cells were treated with
varying doses of Cr(VI) (0 - 100 µM) for 12 h, and cell lysates were prepared and analyzed
for Bcl-2 expression by Western blotting. B, cells were treated for various times (0–24 h)
with Cr(VI) (20 µM) and Bcl-2 expression was determined. Blots were reprobed with βactin antibody to confirm equal loading of samples. The immunoblot signals were
quantified by densitometry, and mean data from independent experiments were normalized
to the result obtained in cells in the absence of Cr(VI) (control). Plots are mean ± S.D. (n =
4). *, p < 0.05 versus non-treated control.
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FIGURE 13. Effect of ROS modulators on Bcl-2 expression. A, H460 cells were either
left untreated or pretreated with MnTBAP (100 µM), catalase (10000 U/ml), LY 83,583
(10 µM) or H2O2 (0.1 mM) for 1 h, followed by Cr(VI) treatment (20 µM) for 12 h. Cell
lysates were then prepared and analyzed for Bcl-2 expression by Western blotting. B, GPx-,
SOD-, or mock-transfected cells were treated with Cr(VI) (10, 20 µM) for 12 h, and Bcl-2
expression was determined by Western blotting. C, H460 and H460 ρ0 cells were treated
with Cr(VI) (10, 20 µM) for 12 h, and Bcl-2 expression was similarly determined. Blots
were reprobed with β-actin antibody to confirm equal loading of samples. Densitometry
was performed to determine the relative expression of Bcl-2 in treated cells compared with
non-treated cells. Plots are mean ± S.D. (n = 4). *, p < 0.05 versus non-treated control.
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FIGURE 14. Effect of ROS on Bcl-2 ubiquitination. A, H460 cells were either left
untreated or pretreated with LAC (10 µM) for 0.5 h, followed by Cr(VI) treatment (20 µM)
for 12 h. Cell lysates were then prepared and analyzed for Bcl-2 expression by Western
blotting. B, subconfluent monolayers of H460 cells overexpressing Bcl-2 were pretreated
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM ) and H2O2 (0.5 mM)
for 1 h. Subsequently, the cells were treated with Cr(VI) (20 µM) for 3 h in the presence of
LAC (10 µM) to prevent proteasome-mediated Bcl-2 degradation. Cell lysates were
immunoprecipitated with anti-myc antibody and the immune complexes were analyzed for
ubiquitin by Western blotting. Analysis of ubiquitin was performed at 3 h post-Cr(VI)
treatment where ubiquitination was found to be maximal. Plots are mean ± S.D. (n = 4). *,
p < 0.05 versus non-treated control.
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Role of Nitric Oxide in Cr(VI)-Induced Apoptosis
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3.1. Abstract
Bcl-2 is a key apoptosis regulatory protein of the mitochondrial death pathway whose
function is dependent on its expression levels. Although Bcl-2 expression is controlled by
various mechanisms, post-translational modifications, such as ubiquitination and
proteasomal degradation, have emerged as important regulators of Bcl-2 function.
However, the underlying mechanisms of this regulation are unclear. We report here that
Bcl-2 undergoes S-nitrosylation by endogenous nitric oxide (NO) in response to multiple
apoptotic mediators and that this modification inhibits ubiquitin-proteasomal degradation
of Bcl-2. Inhibition of NO production by the NO scavenger 2-(4-carboxyphenyl)-4,4,5,5tetramethylimidazoline-1-oxyl-3-oxide and by NO synthase inhibitor aminoguanidine
effectively inhibited S-nitrosylation of Bcl-2, increased its ubiquitination, and promoted
apoptotic cell death induced by Cr(VI). In contrast, NO donors dipropylenetriamine
NONOate and sodium nitroprusside showed opposite effects. Furthermore, it was observed
that NO scavenged ·O2‾ forming peroxynitrite, which was the major reactive nitrogen
species involved in S-nitrosylation of Bcl-2. The effect of NO on Bcl-2 stability was shown
to be independent of its dephosphorylation. Mutational analysis of Bcl-2 further showed
that the two cysteine residues of Bcl-2 (Cys158 and Cys229) are important in the Snitrosylation process and that mutations of these cysteines completely inhibited Bcl-2 Snitrosylation. Treatment of the cells with other stress inducers, including Fas ligand and
buthionine sulfoxide, also induced Bcl-2 S-nitrosylation, suggesting that this is a general
phenomenon that regulates Bcl-2 stability and function under various stress conditions.
These findings indicate a novel function of NO and its regulation of Bcl-2, which provides
a key mechanism for the control of apoptotic cell death and cancer development.
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3.2. Introduction
Bcl-2 is a key apoptosis-regulatory protein of the mitochondrial death pathway(1).
Formation of heterodimers with proapoptotic proteins such as Bax, inhibition of
cytochrome c release, and regulation of mitochondrial transmembrane potential are some of
the mechanisms by which Bcl-2 exerts its antiapoptotic effect (2-4). The oncogenic
potential of Bcl-2 protein is well characterized. It is overexpressed in 70% of breast cancer,
30–60% of prostate cancer, and 90% of colorectal cancer (5, 6). Additionally, its
expression has been reported to be amplified in several apoptosis-resistant lung cell lines
and tumor specimens (7-9). Bcl-2 expression is regulated by various mechanisms,
including dimerization, post-translational modification, transcription, and degradation. Bcl2 degradation is mainly mediated via the ubiquitin-proteasomal pathway, which is a major
system for selective protein degradation in eukaryotic cells (10, 11). Nitric oxide (NO) is an
important signaling molecule produced endogenously from L-arginine in a reaction
catalyzed by NO synthases (12). Subtle changes in its rate of production may critically
impact cellular homeostasis, consequently initiating a variety of cellular signaling
processes, including apoptosis (13). NO has been demonstrated to have both pro- and antiapoptotic role, depending on a variety of factors, including the type of cells involved, redox
state of the cell, and the flux and dose of NO (12). Recent evidence indicates that NO
activates a complex network of responses leading to apoptosis via mitochondrial, death
receptor, p38/mitogen-activated protein kinase, and glyceraldehyde-3-phosphate
dehydrogenase-Siah1 cascades (14-17). The anti-apoptotic effect of NO can be mediated
through a number of mechanisms, such as caspase inactivation, induction of p53 gene
expression, up-regulation of FLIP, and overexpression of Bcl-2 and Bcl-XL with
subsequent inhibition of cytochrome c release from the mitochondria (18-24). NO freely
diffuses across cell membranes and interacts with many other molecules. For instance, it
reacts rapidly with ·O2‾ anions in a diffusion controlled reaction to primarily form
peroxynitrite (ONOO¯) in most cell systems (25). The effects of ONOO- on protein
function are mainly due to its reactivity and covalent modification of tyrosine and/or
cysteine residues (26). One of the well-established mechanisms by which NO through the
formation of ONOO¯ regulates the function of various target proteins is via S-nitrosylation
(27). This post-translational modification of proteins can positively or negatively regulate
various signaling pathways, proteins, and metabolic processes (28). For instance, NO
inhibits the function of NF-κB, JNK and protein kinase C and activates Ras and ryanodine
receptor via S-nitrosylation (29-33). Even though NO has been widely implicated in
apoptosis and its dysregulation, its role in cancer is not well characterized. The
involvement and the role of NO in Cr(VI)-induced apoptosis has never been studied.
The objective of this study was to investigate the role of NO in the regulation of Bcl-2
function in Cr(VI)-induced apoptosis of human lung epithelial cancer cells. Cr(VI) is a
naturally occurring heavy metal that has been associated with lung cancers in various
occupational settings (35-38). This compound is also present in cigarette smoke, and an
increased incidence of lung cancer has been reported in smokers with Cr(VI) exposure (34,
36). Cell death induced by Cr(VI) occurs primarily through apoptosis (39), and its
abnormal regulation has been associated with the initiation of Cr(VI)-induced cancer (40).
Several cellular factors and signaling pathways, such as reactive oxygen species, p53, and
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NF-κB activation have been implicated in Cr(VI)-induced apoptosis and carcinogenicity
(41-43). However, the mechanisms involved in the abnormal regulation of apoptosis in
response to Cr(VI) exposure remain unclear. Elevated levels of Bcl-2 and NO production
have been reported in human lung cancers (7-9, 44-46). In the present study, we found that
NO up-regulates Bcl-2 expression, which provides a key mechanism against Cr(VI)induced apoptosis. The mechanism by which NO regulates Bcl-2 involves S-nitrosylation
of the protein, which was also observed under other stress conditions, including exposure to
death ligand and glutathione depletion. ONOO¯ is the major reactive nitrogen species
involved in S-Nitrosylation of Bcl-2 that prevents its downregulation via the ubiquitinproteasome pathway. Mutational analysis indicated the involvement of Cys158 and Cys229 in
S-nitrosylation and ubiquitination of Bcl-2. These findings reveal the existence of a novel
mechanism of NO-mediated regulation of Bcl-2 that could be important in apoptosis
resistance and the development of lung cancer induced by Cr(VI) and other carcinogens.
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3.3. Materials and Methods
Cells and Reagents
The human lung epithelial cancer cell line NCI-H460 was obtained from the American
Type Culture Collection (Rockville, MD). Cells were cultured in RPMI 1640 medium
(Sigma) containing 5% fetal bovine serum, 2mM L-glutamine, 100 units/ml penicillin, and
100 µg/ml streptomycin in a 5% CO2 environment at 37°C. The NO donor sodium
nitroprusside (SNP), NO inhibitors aminoguanidine (AG) and 2-(4-carboxyphenyl)-4,4,5,5tetramethyl-imidazoline-1-oxy-3-oxide (PTIO), lactacystin, buthionine sulfoximine (BSO),
dithiothreitol (DTT), diaminonaphthalene (DAN), mercury (II) chloride (HgCl2), sodium
hydroxide (NaOH), sulfonilamide, N-1-naphthyl ethylenediamine dehydrochloride, sodium
nitrite (NaNO2), 6-Anilinoquinoline-5,8-quinone (LY-83,583) and sodium dichromate
(Na2Cr2O7.2H2O) [(Cr(VI)] were obtained from Sigma (St. Louis, MO). The NO donor
dipropylenetriamine (DPTA) NONOate, Fas ligand (FasL) and the fluorogenic caspase
substrates IETD amino-4-methylcoumarin (IETD-AMC) and LEHD-AMC were from
Alexis Biochemicals (San Diego, CA). Mn(III)tetrakis (4-benzoic acid) porphyrin
(MnTBAP) was purchased from Calbiochem (La Jolla, CA). The NO fluorescent probe
4,5-diaminofluorescein diacetate (DAF-DA), DHE and the apoptosis dye Hoechst 33342
were from Molecular Probes, Inc. (Eugene, OR). Antibodies for Bcl-2, phospho-Bcl-2
(Ser87), Myc, peroxidase-labeled secondary antibodies, anti-myc agarose beads, and
protein A-agarose were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies
for S-nitrosocysteine, ubiquitin, and β-actin were from Sigma, and the transfecting agent
Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).
Plasmid and Transfection
The Bcl-2 plasmid was generously provided by Dr. Christian Stehlik (West Virginia
University Cancer Center, Morgantown, WV). The open reading frame of Bcl-2 and
ubiquitin were amplified by high fidelity PCR (Stratagene, La Jolla, CA) from
corresponding expressed sequence tags and cloned into pcDNA3 expression vectors
containing N-terminal myc epitope tag. The authenticity of all constructs was verified by
DNA sequencing. Transient transfection was performed using Lipofectamine 2000 reagent
according to the manufacturer’s instructions. The amount of DNA was normalized in all
transfection experiments with pcDNA3. Expression of proteins were verified by Western
blotting or immunoprecipitation.
Generation of Stable Bcl-2 Transfectant
Stable transfectant of Bcl-2 was generated by culturing H460 cells in 60-mm dishes until
they reached 80% confluence. 1 µg of cytomegalovirus-neo vector and 15 µl of
Lipofectamine 2000 with 2 µg of myc-tagged Bcl-2 plasmid were used to transfect the cells
in the absence of serum. After 10 h, the medium was replaced with culture medium
containing 5% fetal bovine serum. Approximately 36 h after transfection, the cells were
digested with 0.03% trypsin and plated onto 75-ml culture flasks and cultured for 24–28
days with G418 selection medium (400 µg/ml). The stable transfectant was identified by
Western blotting of Bcl-2 and was cultured in G418-free RPMI medium for at least two
passages before each experiment.
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Caspase and Apoptosis Assays
Caspase activity was determined by fluorometric assay using the enzyme substrate IETDAMC for caspase-8 and LEHD-AMC for caspase-9, which are specifically cleaved by the
respective enzymes at the Asp residue to release the fluorescent group, AMC. Cell extracts
containing 50 µg of protein were incubated with 100 mM HEPES containing 10% sucrose,
10 mM dithiothreitol, 0.1% 3-((3-cholamidiopropyl)-1) propane sulfonate, and 50 µM
caspase substrate in a total reaction volume of 0.25 ml. The reaction mixture was incubated
for 60 min at 37°C and quantified fluorometrically at the excitation and emission
wavelengths of 380 and 460 nm, respectively. Apoptosis was determined by incubating the
cells with 10 µg/ml Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the
percentage of cells having intensely condensed chromatin and/or fragmented nuclei by
fluorescence microscopy (Axiovert 100; Carl Zeiss) using Pixera software.
NO Detection
Intracellular NO production was determined by flow cytometry and fluorescence
microscopy using NO-specific probe DAF-DA. For flow cytometric analysis, cells (1 x
106/ml) were incubated with the probe (10 µM) for 30 min at 37°C, after which they were
washed, resuspended in phosphate-buffered saline (PBS), and analyzed for DAF
fluorescence intensity using a 488-nm excitation beam and a 538-nm bandpass filter
(FACS calibur; Becton-Dickinson). For fluorescence microscopy, cells were incubated
with the probe as described above and then examined for DAF fluorescence using Carl
Zeiss Axiovert microscope.
Griess Assay
NO production was confirmed by measuring its nitrite by-product using Griess assay. Cell
supernatants (50 µl) were incubated with 50 µl of Griess reagent containing 0.1% N-1naphthyl ethylenediamine dehydrochloride and 1% sulfanilamide for 10 min at room
temperature. The optical density of the samples was measured using a microplate reader
(model 550; Bio-Rad) at 550 nm. NO concentration was calculated from the standard curve
produced during each assay by using NaNO2 dissolved in 15 mM HEPES, pH 7.5.
Western Blotting
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF,
100 mM PMSF, and protease inhibitor mixture for 20 min on ice. After insoluble debris
was precipitated by centrifugation at 14,000 x g for 15 min at 4°C, the supernatants were
collected and assayed for protein content using BCA method. An equal amount of proteins
per sample (15 µg) were resolved on 10% SDS-PAGE and transferred onto a 0.45-µm
nitrocellulose membrane. The transferred membranes were blocked for 1 h in 5% non-fat
dry milk in TBST (25 mM Tris-HCl, pH 7.4, 125 mM NaCl, 0.05% Tween 20) and
incubated with the appropriate primary antibodies and horseradish peroxidase-conjugated
secondary antibodies. The immune complexes were detected by chemiluminescence
(Supersignal West Pico; Pierce) and quantified by imaging densitometry using UN-SCANIT automated digitizing software (Silk Scientific, Orem, UT). Mean densitometry data from
independent experiments were normalized to the control. The data were presented as mean
± S.D. and analyzed by Student’s t test.
52

Immunoprecipitation
Cells were washed after treatments with ice-cold PBS and lysed in lysis buffer at 4°C for
20 min. After centrifugation at 14,000 x g for 15 min at 4°C, the supernatants were
collected, and the protein content was determined as described. Cleared lysates were
normalized, and 60 µg of proteins were incubated with 8 µl of anti-myc-agarose beads
(Santa Cruz Biotechnology) diluted with 12 µl of protein A-agarose for 4 h at 4°C. The
immune complexes were washed three times with 500 µl of lysis buffer, resuspended in 2 x
Laemmli sample buffer, and boiled at 95°C for 5 min. The immune complexes were
separated by 10% SDS-PAGE and analyzed by Western blot as described.
Fluorometric Measurement of S-Nitrosylation
S-Nitrosylation of Bcl-2 was measured as previously described (31, 47). In brief, cells were
treated, harvested, lysed, and subjected to immunoprecipitation. The immunoprecipitates
were rinsed four times with lysis buffer and twice with PBS. The pellets were resuspended
in 500 µl of PBS and incubated with HgCl2 (200 µM) and diaminonaphthalene (DAN)
(200 µM) for 0.5 h in dark at room temperature followed by the addition of 1 M NaOH. A
fluorescent triazole generated from the reaction between DAN and NO released from Snitrosylated Bcl-2 was quantified using a fluorometer (FLUOstar OPTIMA, BMG Inc.,
Durham, NC) at the excitation and emission wavelengths of 375 and 450 nm, respectively.
Site-directed Mutagenesis of Bcl-2
Mutant Bcl-2 plasmids were constructed using the above-mentioned human Bcl-2 plasmid
as template. Two sets of forward and reverse primers were constructed to introduce
mutations at Cys158 and Cys229: C158A, CGGTGGGGTCATGGCTGTGGA
GAGCGTCAACCG (forward) and CGGTTGACGCTCTCCACAGCCATGACCCCAG
(reverse); C229A, GGCCCTGGTGGGAGCTGCCATCACCCTGGGTGCC (forward) and
GGCACCCAGGGTGATGGCAGCTCCCACCAGGGCC (reverse). Three mutant
plasmids (C158A, C229A, and a plasmid with both mutations) were constructed using the
QuikChange XL site-directed mutagenesis kit (Stratagene). Mutagenesis was confirmed by
automated nucleotide sequencing.
Proteasome Activity Assay
Proteasome activity was measured using an assay kit from CHEMICON (Temecula, CA),
according to the manufacturer’s protocol. Briefly, cells were washed after treatments with
ice-cold PBS and lysed in lysis buffer at 4°C for 20 min. After centrifugation at 14,000 x g
for 15 min at 4 °C, the supernatants were collected and protein content was determined by
BCA method. Cleared lysates were normalized, and 20 µg of proteins were incubated with
the proteasome substrate LLVY-AMC at 37°C for 1 h. The fluorophore AMC obtained
after cleavage from the labeled substrate was quantified at the excitation and emission
wavelengths of 380 and 460 nm, respectively.
ROS Detection
Intracellular ·O2‾ production was determined by spectrofluorometry using DHE as the
fluorescence probe. Cells (1x106/ml) were incubated with the fluoresecent probe (10 µM)
for 30 min at 37ºC, after which they were washed, resuspended in phosphate buffered
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saline (PBS), and analyzed for DHE fluorescence at the excitation and emission
wavelengths of 535 nm and 617 nm) using FLUOstar OPTIMA (BMG, Inc.)
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3.4. Results
NO Inhibits Cr(VI)-induced Apoptosis – As shown in the previous aim, Cr(VI) induces
apoptosis in a dose-dependent manner mainly via the mitochondrial pathway. To
investigate the potential role of NO in the regulation of Cr(VI)-induced apoptosis, cells
were treated with Cr(VI) in the presence or absence of various NO inhibitors and donors,
and apoptosis was determined by Hoechst assay. Figs. 1, A and B, show that NO inhibitors
AG and PTIO effectively increased apoptotic cell death induced by Cr(VI), whereas NO
donors SNP and DPTA NONOate inhibited this effect in a dose-dependent manner.
Caspase activity assays similarly showed that the NO inhibitor AG and the NO donor SNP,
respectively, increased and decreased the effect of Cr(VI) on capase-9 activation (Fig. 1C).
These results indicate that NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis.
Effect of NO Modulators on Cellular NO Level - To provide a relationship between the
apoptotic response and NO modulation by the test agents, we performed flow cytometric
analysis assessing the effect of test agents on cellular NO production using the fluorescent
probe DAF DA. Fig. 2, A and B, show that the NO inhibitors AG and PTIO significantly
inhibited cellular NO production induced by Cr(VI), whereas the NO donors SNP and
DPTA NONOate promoted this effect. Fig. 2C shows fluorescence micrographs of cells
treated with Cr(VI) in the presence or absence of NO modulators. Since Cr(VI) exposure is
known to produce ROS (39, 40) and due to the report challenging the specificity of DAF
DA to NO in cells undergoing oxidative and nitrosative stress (50), we confirmed this
effect by the Griess method. Griess assay measures nitrite, which is the stable breakdown
product of NO. Fig. 2D shows that NO inhibitors inhibited cellular nitrite production
induced by Cr(VI), whereas the NO donors SNP and DPTA NONOate increased its levels.
These results indicate the modulation of cellular NO levels by the test agents and support
the role of NO in the regulation of Cr(VI)-induced apoptosis.
Effect of NO Modulators on Bcl-2 Expression – Having demonstrated the role of Bcl-2 in
Cr(VI)-induced apoptosis in the previous aims, we next examined the potential regulation
of Bcl-2 by NO in H460 cells. We treated the cells with Cr(VI) in the presence or absence
of various NO modulators, including AG, PTIO, SNP, and DPTA NONOate, and the
expression level of Bcl-2 was similarly determined. Fig. 3A shows that the NO inhibitors
AG and PTIO significantly increased the down-regulation of Bcl-2 by Cr(VI), whereas the
NO donors SNP and NONOate inhibited this down-regulation and further increased the
Bcl-2 expression level over control level. Fig. 3B shows the effect of AG and PTIO alone
as controls on Bcl-2 expression. Since previous studies have shown that Bcl-2 is rapidly
down-regulated by proteasomal degradation (10), we tested whether Bcl-2 down-regulation
by Cr(VI) is also mediated by this pathway. Cells were treated with lactacystin, a highly
specific proteasome inhibitor, and its effect on Cr(VI)-induced Bcl-2 down-regulation was
determined by immunoblotting. The result in Fig. 3A shows that lactacystin completely
inhibited Bcl-2 down-regulation induced by Cr(VI), indicating a dominant role of
proteasome-mediated degradation of Bcl-2 by Cr(VI).
Effect of NO on Bcl-2 Phosphorylation - Accumulating evidence indicates that Bcl-2
phosphorylation induces a conformational change in Bcl-2 that controls its stability and
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apoptotic function (51-53). Phosphorylation of Bcl-2 at Thr 74 and Ser 87 has been shown
to regulate its stability and dephosphorylation at Ser 87 is the initial step of Bcl-2
degradation (10, 54). Since our results demonstrated that NO can prevent Bcl-2
degradation, we further investigated the effect of NO on Bcl-2 phosphorylation. Cells were
treated with Cr(VI) in the presence or absence of various NO modulators, and their effect
on Bcl-2 phosphorylation was determined by Western blot using phosphospecific Bcl-2
(Ser 87) antibody. The results show that Cr(VI) had minimal effect on Bcl-2
phosphorylation, and likewise NO donors and inhibitors had no significant effect on the
phosphorylation level (Fig. 3C). These results suggest that NO regulates Bcl-2 stability via
a mechanism that is independent of its phosphorylation.
NO Prevents Cr(VI)-induced Ubiquitination of Bcl-2 - To further investigate the
mechanism by which NO inhibits Cr(VI)-induced Bcl-2 degradation, we analyzed
ubiquitination of Bcl-2 in response to Cr(VI) treatment by immunoprecipitation. Cells
overexpressing myc-Bcl-2 were treated with Cr(VI) in the presence or absence of NO
donors and inhibitors. Cell lysates were prepared and immunoprecipitated using anti-myc
antibody. The resulting immune complexes were analyzed for ubiquitination by Western
blot using anti-ubiquitin antibody. The results show that Cr(VI) was able to induce
ubiquitination of Bcl-2 and that NO inhibitors AG and PTIO increased this effect (Fig. 4).
In contrast, NO donors SNP and DPTA NONOate inhibited Bcl-2 ubiquitination, thus
supporting the inhibitory role of NO in ubiquitin-mediated degradation of Bcl-2 by Cr(VI).
NO-mediated S-Nitrosylation of Bcl-2 Inhibits its Ubiquitination - NO can control the
function of several proteins by S-nitrosylation process (55-57). To determine whether NO
could nitrosylate Bcl-2 and whether this process could affect Bcl-2 stability, we performed
immunoprecipitation experiments evaluating the effect of NO on Bcl-2 S-nitrosylation.
Cells expressing ectopic Bcl-2-myc were treated with Cr(VI) and NO modulators, and cell
lysates were immunoprecipitated and analyzed by Western blot analysis using anti-Snitrosocysteine antibody and by spectrofluorometry. Figs. 5, A and B, show that treatment
of the cells with Cr(VI) induced S-nitrosylation of Bcl-2, and this effect was enhanced by
NO donors SNP and DPTA NONOate. In contrast, NO inhibitors AG and PTIO inhibited
this nitrosylation process. These results suggest that NO, through its ability to nitrosylate
Bcl-2, may interfere with the ubiquitination process and inhibit Bcl-2 degradation by the
proteasome. To test this possibility, we treated cells with a known inhibitor of Snitrosylation, DTT (58, 59), and its effects on Bcl-2 S-nitrosylation and ubiquitination were
determined. The results show that DTT was able to prevent S-nitrosylation of Bcl-2 (Fig.
5A). Furthermore, it negated the effect of NO donors SNP and DPTA NONOate on Bcl-2
ubiquitination in Cr(VI)-treated cells (Fig. 5C). These results indicate that S-nitrosylation
might be a key mechanism utilized by NO to regulate ubiquitination and degradation of
Bcl-2 by the proteasome. Recent reports suggest that NO could directly regulate
proteasome activity by S-nitrosylation of E3 ubiquitin ligases (parkin, Mdm2) (60, 61). To
confirm that the effect observed on Bcl-2 ubiquitination is specifically due to its Snitrosylation, we treated cells with DTT in the presence and absence of Cr(VI) and
determined its effects on proteasome activity. Cells expressing ectopic Bcl-2-myc were
treated with Cr(VI) and DTT, and cell lysates were immunoprecipitated and analyzed for
proteasome activity by spectrofluorometry. The results show that DTT had no significant
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effect on proteasomal activity as compared with Cr(VI) treatment alone (Fig. 5D),
confirming that this effect is specifically due to modification and S-nitrosylation of Bcl-2.
S-Nitrosylation of Bcl-2 under Other Stress Conditions - To determine whether Snitrosylation of Bcl-2 was a general phenomenon, we performed immunoprecipitation
experiments evaluating the effect of other stress inducers including FasL and BSO on Bcl-2
S-nitrosylation. The results show that these test agents also induced S-nitrosylation of Bcl-2
(Figs. 6, A and B), suggesting that this process is a general phenomenon that regulates the
anti-apoptotic function of Bcl-2.
Mutations at Cys158 and Cys229 Prevents Bcl-2 S-Nitrosylation - To confirm Bcl-2 Snitrosylation and to determine the cysteine residue(s) that may be involved in the process,
we constructed Bcl-2 mutant plasmids replacing the two cysteines in Bcl-2 with alanines.
The mutant plasmids and the original Bcl-2 plasmid were individually introduced into
H460 cells by transient transfection. Transfected cells were treated with Cr(VI), and cell
lysates were prepared and analyzed for S-nitrosylated Bcl-2 by Western blotting using antiS-nitrosocysteine antibody. The results show that treatment of the cells with Cr(VI) induced
S-nitrosylation of Bcl-2, which was completely inhibited by one or both cysteine mutations
(Fig. 7, A and B). The results also show that although both cysteines undergo Snitrosylation in response to Cr(VI) treatment, Cys229 is the major site of Bcl-2 nitrosylation.
To test whether S-nitrosylation of Bcl-2 could stabilize the protein and prevent its
degradation, we tested the effect of mutant plasmids on Bcl-2 ubiquitination. Cells were
transfected with the plasmids and treated with Cr(VI) as described. Cell lysates were
immunoprecipitated and analyzed by Western blot using anti-ubiquitin antibody. The
results show that cysteine mutations led to increased ubiquitination of Bcl-2 by Cr(VI) (Fig.
8A), indicating that S-nitrosylation of the protein prevents its ubiquitination and subsequent
degradation. We also observed that transient transfection with the mutant plasmids
increased apoptotic response to Cr(VI) exposure as compared to the wild-type plasmid
(Fig. 8B). Increased apoptosis was observed in cells transfected with Cys229 mutant plasmid
as compared to cells transfected with Cys158 mutant plasmid confirming that Cys229 is the
major site of Bcl-2 nitrosylation. This observation indicates that S-nitrosylation of Bcl-2
stabilizes the protein and maintains its anti-apoptotic function.
NO Reacts with ·O2‾ to Form ONOO¯ that Causes S-nitrosylation of Bcl-2 – We
demonstrate that NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis by stabilizing
Bcl-2 protein via S-nitrosylation. However, recent evidences suggest that ONOO¯ is the
major nitrogen species involved in S-nitrosylation, specifically in systems with increased
·O2‾ production. As shown in the previous aim, ·O2‾ mediates Cr(VI)-induced apoptosis by
the down-regulation of Bcl-2 protein, we therefore tested the possibility of the involvement
of ONOO¯ in Bcl-2 nitrosylation in response to Cr(VI) exposure. H460 cells were treated
with ·O2‾ modulators in addition to Cr(VI) and were assessed for NO levels by
spectrofluorometry. Similarly, we treated cells with NO modulators and tested the effect on
·O2‾ level. We observed increased NO levels in cells treated with ·O2‾ inhibitor (MnTBAP)
and decreased levels in cells treated with ·O2‾ donor (LY-83,583) (Fig. 9A). Similarly,
treatment with NO donors decreased ·O2‾ levels whereas NO inhibitors increased ·O2‾
levels (Fig. 9B). This suggested a direct correlation between NO and ·O2‾ levels and
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indicated that NO may be scavenging ·O2‾ forming ONOO¯ in response to Cr(VI)
exposure. We also found that ONOO¯ donor (SIN1) had a protective effect in Cr(VI)
induced apoptosis (Fig. 10, A and B). Furthermore, ·O2‾ modulators affected S-nitrosylation
with donors showing increased effect and inhibitors completely blocking the effect (Fig. 10
C). These results suggest that ONOO¯ formation in response to Cr(VI) treatment leads to
S-nitrosylation of Bcl-2 that prevents apoptosis.
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3.5. Discussion
Many cell-based studies have demonstrated that overexpression of Bcl-2 increases
resistance to apoptotic cell death induced by various DNA-damaging agents, which is an
important feature of malignant cells (7-9). Similarly, NO has been shown to be elevated in
many cancer cells (44-46); however, its potential role in the regulation of Bcl-2 and the
underlying mechanisms has not been demonstrated. In the present study, we show that NO,
through the formation of ONOO¯ regulates Bcl-2 protein via S-nitrosylation and that this
mechanism stabilizes the protein, maintaining its anti-apoptotic function. In the previous
aims, we have established that ROS, specifically ·O2‾, mediates Cr(VI)-induced apoptosis
via the mitochondrial death pathway. Further, we showed that Bcl-2 overexpression
inhibited Cr(VI)-induced apoptosis and ROS mediated its effect by down-regulation of
Bcl-2. In this study, we observed that the addition of NO donors SNP and DPTA NONOate
effectively inhibited this down-regulation and decreased cell death (Figs. 1 and 3). In
contrast, NO inhibitors AG and PTIO showed opposite effects, indicating the anti-apoptotic
role of NO and its regulation of Bcl-2 in the test system. It has been reported that apoptotic
doses of Cr(VI) caused mitochondrial instability (62). The anti-apoptotic function of Bcl-2
is closely associated with its expression levels. Although Bcl-2 expression is controlled by
various mechanisms, post-translational modifications, such as ubiquitination and
phosphorylation, have emerged as important regulators of Bcl-2 function (7, 8). Our results
show that down-regulation of Bcl-2 by Cr(VI) was associated with an increase in Bcl-2
ubiquitination and proteasomal degradation (Figs. 4 and 5). The ability of the proteasome
inhibitor lactacystin to inhibit Bcl-2 down-regulation strongly supports the role of the
proteasomal pathway in Bcl-2 regulation. The NO donors SNP and DPTA NONOate
inhibited Bcl-2 ubiquitination by Cr(VI), whereas the NO inhibitors AG and PTIO
promoted this effect (Fig. 4). These results indicate that NO regulates Bcl-2 stability by
preventing its degradation via the ubiquitin-proteasomal pathway. It has been reported that
Bcl-2 stability is regulated by phosphorylation at Thr 74 and Ser 87 and dephosphorylation
at Ser 87 in response to proapoptotic stimuli, such as TNF-α, is the initial step of Bcl-2
degradation (10). Since NO prevented down-regulation of Bcl-2 in our system, we studied
the effect of NO on Bcl-2 phosphorylation. However, we found that NO had no significant
effect on Bcl-2 phosphorylation (Fig. 3), indicating that NO may regulate Bcl-2 stability
through a mechanism that does not require Bcl-2 dephosphorylation. TNF-α is a death
ligand that induces apoptosis via the death receptor pathway, whereas Cr(VI) induces cell
death primarily via the mitochondrial pathway. Therefore, its mechanism of Bcl-2
regulation may be different from Cr(VI). Our results suggest that dephosphorylation of Bcl2 might not be a necessary event for triggering Bcl-2 ubiquitination and that different
mechanisms of Bcl-2 regulation exist and are utilized by different apoptosis-inducing
agents.
The mechanism by which NO regulates Bcl-2 ubiquitination is not known but may involve
S-nitrosylation of the protein, which may prevent its recognition and subsequent attachment
of ubiquitin by the enzyme ubiquitin ligases. S-Nitrosylation of proteins, such as FLIP and
caspases, has been reported to modulate their apoptosis activities (19, 55-57). To determine
the effect of NO on Bcl-2 ubiquitination and degradation, we analyzed NO-mediated Snitrosylation of Bcl-2 in Cr(VI)-treated cells. We found that Cr(VI) induced S-nitrosylation
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of Bcl-2 and that this effect was inhibited by the NO inhibitors AG and PTIO and enhanced
by the NO donors SNP and PTIO (Fig. 5). Inhibition of S-nitrosylation by the known
inhibitor DTT completely inhibited the effect of NO on Bcl-2 ubiquitination (Fig. 5D), thus
confirming the protective role of S-nitrosylation on Bcl-2 ubiquitination. Recent evidence
suggests that NO can nitrosylate E3 ubiquitin ligase (parkin, Mdm2) (60, 61). SNitrosylation of this enzyme inhibits its activity and protective function. To test whether
the effect of NO was due to S-nitrosylation of Bcl-2 specifically or due to nitrosylation of
ubiquitin ligase, we performed a proteasome activity assay and tested the effect of DTT on
the enzyme activity in the presence or absence of Cr(VI). We found that DTT had no
significant effect on proteasomal activity as compared with Cr(VI) treatment alone (Fig.
5D). If the effect on Bcl-2 degradation was due to S-nitrosylation of ubiquitin ligase,
treatment with DTT should have shown an increase in proteasomal activity. This result
suggests that the effect of NO on Bcl-2 stability was specifically due to S-nitrosylation of
Bcl-2. This result was confirmed by mutation assay in which the cysteine residues of Bcl-2
(Cys158 and Cys229) were mutated to alanines. Such mutations resulted in a complete
inhibition of Bcl-2 S-nitrosylation by Cr(VI) (Fig. 7 and 8). The stronger inhibitory effect
of the Cys229 mutation indicates that this cysteine is the major site of Bcl-2 S-nitrosylation.
Further, cysteine mutations led to increased ubiquitination and increased apoptosis,
confirming that S-nitrosylation of Bcl-2 prevents its ubiquitination and stabilizes the
activity of the protein. Recent evidences suggest that under physiological conditions NO
does not react with thiol (-SH) groups directly as it requires the presence of a strong
electron acceptor such as Fe3+(63). The kinetically favored reaction for NO is interaction
with ·O2‾ which leads to the formation of ONOO¯(64). NO derived reactive species such as
ONOO¯ readily reacts with thiols to form nitrosothiols (RS-NO). As shown in the previous
aim, we observed that ·O2‾ is the major ROS involved in Cr(VI)-induced apoptosis, we
therefore tested the possibility of ONOO¯ involvement in S-nitrosylation of Bcl-2. We
observed a direct correlation between NO and ·O2‾ levels, with the increase in one leading
to the decrease in the levels of the other and vice versa (Fig. 9). We observed that ·O2‾
donor further increased Cr(VI) induced Bcl-2 S-nitrosylation and ·O2‾ inhibitors reduced it
to the control levels. Further, SIN1 treatment decreased Cr(VI) induced apoptosis
significantly. All these results suggest that ONOO¯ causes S-nitrosylation of Bcl-2 that
leads to its stabilization (Fig. 10).
Since this study shows a novel mechanism of Bcl-2 regulation by S-nitrosylation, we
further tested the generality of this process by treating the cells with other well established
stress inducers, including FasL and BSO. BSO is an amino acid that depletes cells of
glutathione, resulting in free radical-induced apoptosis (65). FasL is a death ligand that is
known to induce apoptosis via the death receptor pathway (48, 49). We observed that Bcl-2
was S-nitrosylated in response to these stress inducers, suggesting that S-nitrosylation is a
general process that can regulate Bcl-2 stability and function under various stress
conditions (Fig. 6). In summary, our data provide evidence that NO plays an important role
as a negative regulator of Cr(VI)-induced cell death through the mitochondrial pathway by
preserving Bcl-2 stability and function. NO exerts this effect through the formation of
ONOO¯, which nitrosylates the protein and inhibit its ubiquitination and proteasomal
degradation. S-Nitrosylation of Bcl-2 was observed to be a general mechanism that can
regulate its stability under various stress conditions. In demonstrating S-nitrosylation of
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Bcl-2, we document a novel layer of regulation that links NO signaling with Bcl-2 stability
and function, which may represent an important mechanism that controls cancer
development and progression. Since increased NO production and Bcl-2 expression have
been associated with several human tumors, NO may be one of the key regulators of cell
death resistance and cancer development through its ability to S-nitrosylate Bcl-2. This
finding on the novel function of NO on Bcl-2 regulation may have important implications
in carcinogenesis and its prevention.
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FIGURE 1. Effect of NO modulators on Cr(VI)-induced apoptosis and caspase
activation. A, subconfluent (90%) monolayers of H460 cells were pretreated with the NO
donor SNP (500 µg/ml) or DPTA NONOate (400 µM) or with the NO inhibitor AG (300
µM) or PTIO (300 µM) for 1 h. The cells were then either left untreated or treated with
Cr(VI) (20 µM) for 12 h and analyzed for apoptosis by Hoechst assay. B, dose effect of NO
modulators on Cr(VI)-induced apoptosis. Cells were treated with Cr(VI) (20 µM) for 12 h
after pretreatment with SNP (250, 500, and 750 µg/ml), DPTA NONOate (200, 400, and
600 µM), AG (100, 300, and 500 µM), or PTIO (100, 300, and 500 µM) for 1 h. C, cells
were similarly treated with Cr(VI) with or without NO modulators, and caspase-9 activity
was determined by fluorometric analysis. Plots are mean ± S.D. (n≥ 3). *, p < 0.05 versus
Cr(VI)-treated control.
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FIGURE 2. Effect of NO modulators on cellular NO levels. A and B, flow cytometric
analysis of NO production in H460 cells. Cells were treated with the NO inhibitor AG (300
µM) or PTIO (300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400
µM) for 1 h, after which they were treated with Cr(VI) (20 µM) and analyzed for NO levels
by flow cytometry using DAF DA as the fluorescent probe. Plots show relative DAF
fluorescence intensity determined at the peak response time of 1 h after Cr(VI) treatment.
C, fluorescence micrographs of treated cells from above. D, measurement of nitrite
production (direct breakdown product of NO) by the Griess method. Cells were treated as
mentioned above, and 50 µl of the culture medium in each plate was collected and analyzed
for NO production by Griess method. Values are mean ± S.D. (n ≥ 3). *, p < 0.05 versus
non-treated control; **, p < 0.05 versus Cr(VI)-treated control.
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FIGURE 3. Effect of NO modulators on Bcl-2 expression and phosphorylation. A,
H460 cells were pretreated for 1 h with one of the following agents: SNP (500 µg/ml),
DPTA NONOate (400 µM), AG (300 µM), PTIO (300 µM), and lactacystin (LAC) (10
µM). The cells were then treated with Cr(VI) (20 µM) for 12 h, and cell lysates were
prepared and analyzed for Bcl-2 expression by Western blots using anti-Bcl-2 antibody. B,
H460 cells were treated with AG (300 µM) and PTIO (300 µM) for 12 h, and cell lysates
were prepared and analyzed for Bcl-2 expression by Western blots using anti-Bcl-2
antibody. C, H460 cells were pretreated for 1 h with SNP (500 µg/ml), DPTA NONOate
(400 µM), AG (300 µM) and PTIO (300 µM) and were then treated with Cr(VI) (20 µM)
for 12 h, and cell lysates were prepared and analyzed for Bcl-2 phosphorylation by Western
blots using phospho-specific Bcl-2 (Ser 87) antibody. Densitometry was performed to
determine the relative levels of Bcl-2 and phospho-Bcl-2 after reprobing the blots with βactin antibody. Plots are mean ± S.D. (n = 4). *, p < 0.05 versus non-treated control.
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FIGURE 4. Effect of NO on Bcl-2 ubiquitination. Subconfluent monolayers of H460
cells overexpressing Bcl-2 were pretreated with the NO inhibitor AG (300 µM) or PTIO
(300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400 µM) for 1 h.
Subsequently, the cells were treated with Cr(VI) (20 µM) for 3 h in the presence of
lactacystin (10 µM) to prevent proteasome-mediated Bcl-2 degradation. Cell lysates were
immunoprecipitated with anti-myc antibody, and the immune complexes were analyzed for
ubiquitin by Western blotting. Analysis of ubiquitin was performed at 3 h post-Cr(VI)
treatment, where ubiquitination was found to be maximal. Data are mean ±S.D. (n = 4). *,
p < 0.05 versus non-treated control. **, p < 0.05 versus Cr(VI)-treated control.
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FIGURE 5. Effect of NO on S-nitrosylation and ubiquitination of Bcl-2. A, subconfluent
monolayers of H460 cells overexpressing Bcl-2 were pretreated with SNP (500 µg/ml),
DPTA NONOate (400 µM), AG (300 µM), PTIO (300 µM), or DTT (10 mM) for 1 h. The
cells were then treated with Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for
immunoprecipitation using anti-myc antibody. The resulting immune complexes were
analyzed for S-nitrosocysteine by Western blotting. Densitometry was performed to
determine the relative S-nitrosocysteine levels after reprobing the membranes with antiBcl-2 antibody. B, S-nitrosylation of Bcl-2 determined by spectrofluorometry.
Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM DAN. NO
released from S-nitrosylated Bcl-2 was quantified at 375/450 nm. C, effect of NO
modulators and DTT on Cr(VI)-induced Bcl-2 ubiquitination. Cells overexpressing Bcl-2
were treated with the indicated test agents in the presence of lactacystin (10 µM). Cell
lysates were then immunoprecipitated with anti-myc antibody, and the immune complexes
were analyzed for ubiquitin. D, cells overexpressing Bcl-2 were pretreated with DTT (10
mM) for 0.5 h and then treated with Cr(VI) (20 µM) for 3 h. Proteasome activity was
determined spectrofluorometrically at 380/460 nm. Data are mean ± S.D. (n = 4). *, p <
0.05 versus non-treated control. **, p < 0.05 versus Cr(VI)-treated controls. #, p < 0.05
versus NO-modulated controls.
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FIGURE 6. Effect of stress inducers on Bcl-2 S-nitrosylation. A, Subconfluent
monolayers of H460 cells overexpressing Bcl-2 were treated with FasL (200 ng/ml), BSO
(100 µM), or Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for
immunoprecipitation using anti-Myc antibody. The resulting immune complexes were
analyzed for S-nitrosocysteine by Western blotting. Densitometry was performed to
determine the relative S-nitrosocysteine levels after reprobing of the membranes with antiBcl-2 antibody. B, S-nitrosylation of Bcl-2 determined by spectrofluorometry.
Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM DAN. NO
released from S-nitrosylated Bcl-2 was quantified at 375/450 nm. Data are mean ± S.D. (n
= 4). *, p < 0.05 versus non-treated control.
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FIGURE 7. Effect of cysteine mutations on S-nitrosylation of Bcl-2. A, H460 cells were
transiently transfected with myc-tagged original Bcl-2 plasmid (WT) or with myc-tagged
C158A, C229A, or C158A/C229A mutant plasmid. 36 h later, the cells were treated with or
without Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for immunoprecipitation
using anti-myc antibody. The immune complexes were analyzed for S-nitrosocysteine by
Western blotting. Densitometry was performed to determine the relative S-nitrosocysteine
levels after reprobing of the membranes with anti-Bcl-2 antibody. B, S-nitrosylation of Bcl2 determined by spectrofluorometry. Immunopellets from above were incubated with 200
µM HgCl2 and 200 µM DAN. NO released from S-nitrosylated Bcl-2 was quantified at
375/450 nm. Data are mean ± S.D. (n = 4). *, p < 0.05 versus non-treated control; **, p <
0.05 versus Cr(VI)-treated control.

68

A

B

FIGURE 8. Effect of cysteine mutations on ubiquitination of Bcl-2. A, H460 cells were
transiently transfected with myc-tagged original Bcl-2 plasmid (WT) or with myc-tagged
C158A, C229A, or C158A/C229A mutant plasmid. 36 h later, the cells were treated with or
without Cr(VI) (20 µM) for 3 h, and cell lysates were prepared for immunoprecipitation
using anti-myc antibody. Immunoprecipitates were prepared as described above and
analyzed for ubiquitin by Western blotting. Data are mean ± S.D. (n = 4). B, H460 cells
transfected with original (WT) and mutant plasmids as mentioned above were exposed to
Cr(VI) (10, 20 µM) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342
assay.

69

A

B

FIGURE 9. NO reacts with ·O2‾ to form ONOO‾. A, H460 cells were treated with ·O2‾
donor LY-83,583 and ·O2‾ scavenger MnTBAP for 0.5 h, after which they were treated
with Cr(VI) (20 µM) and analyzed for NO levels by spectrofluorometry using DAF-DA as
the fluorescent probe. B, Cells were treated with the NO inhibitor AG (300 µM) or PTIO
(300 µM) or with the NO donor SNP (500 µg/ml) or DPTA NONOate (400 µM) for 0.5 h,
after which they were treated with Cr(VI) (20 µM) and analyzed for ·O2‾ levels by
spectrofluorometry using DHE as the fluorescent probe. Plots show relative DAF and DHE
fluorescence intensity determined at the peak response time of 1 h after Cr(VI) treatment. *,
p < 0.05 versus non-treated control; **, p < 0.05 versus Cr(VI)-treated control.
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FIGURE 10. ONOO‾ inhibits apoptosis and causes S-nitrosylation of Bcl-2. A and B,
subconfluent (90%) monolayers of H460 cells were exposed to Cr(VI) (20 µM) in the
presence or absence of SIN-1 (100 µg/ml), and the cells were analyzed for apoptosis by
Hoechst 33342 assay after 12 h exposure. E, Subconfluent monolayers of H460 cells
overexpressing Bcl-2 were treated with LY 83,583 and MnTBAP followed by Cr(VI) (20
µM) treatment for 3h, and cell lysates were prepared for immunoprecipitation using antimyc antibody. Immunopellets from above were incubated with 200 µM HgCl2 and 200 µM
DAN. NO released from S-nitrosylated Bcl-2 was quantified at 375/450 nm by
spectrofluorometry. *, p < 0.05 versus non-treated control.
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CHAPTER IV
Malignant Transformation of Human Lung Epithelial Cells in
Response to Chronic Cr(VI) Exposure
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4.1. Abstract
Exposure to Cr(VI) is associated with the incidence of lung cancer in humans. Human lung
cancer manifests mostly as epithelial cell derived carcinomas; however, it is still unknown
whether human lung epithelial cells are directly susceptible to Cr(VI)-induced malignant
transformation. This study was designed to determine whether the non-tumorigenic human
lung epithelial Beas-2B cell line could be malignantly transformed in vitro by subjecting
them to long-term Cr(VI) exposure. Additionally, human lung cancer epithelial H460 cells
were used and the effects in Beas-2B cells were compared to this cell-type. Beas-2B and
H460 cells were continuously exposed to 5 µM Cr(VI). After 24 weeks of exposure, Cr(VI)
exposed cells exhibited loss of contact inhibition and increased colony formation in soft
agar as compared to the passage-matched original cell-lines. Further, an increase in
proliferation, invasion and migration rates was observed in the transformed cells. Cr(VI)
transformed cells showed decreased ROS production and apoptosis as well as an increase
in NO levels and inhibition of Bcl-2 down-regulation. This confirmed our earlier
observations that dysregulation of ROS mediated Cr(VI)-induced apoptosis by NO through
the stabilization of Bcl-2 is an important molecular event in the development of apoptosis
resistant phenotype in response to Cr(VI) exposure. This is the first report demonstrating
Cr(VI)-induced malignant transformation of a human lung epithelial cell line and provides
an important in vitro model for studying the mechanisms involved Cr(VI)-induced
carcinogenesis in humans. This study strongly fortifies the potential role of Cr(VI) in lung
cancer.
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4.2. Introduction
Lung cancer is the leading cause of cancer mortality worldwide, with over 1,000,000
deaths annually (1). In US, 160,440 deaths were attributed to cancer of the lung and
bronchus in 2003 (1, 2). Even though it is one of the major fatalities, the etiology of lung
cancer remains poorly understood. Current research indicates that long-term exposure to
inhaled carcinogens has the greatest impact on the risk of lung cancer. Inhalation of Cr(VI)
compounds has been associated with the induction of human lung cancer for more than a
century (3). In US, Machle and Gregorius reported the first epidemiologic evidence to
demonstrate increased lung mortality among chromium-exposed workers (4).
Subsequently, several epidemological studies in the last few decades have confirmed that
exposure to Cr(VI) in chrome plating, electroplating, leather tanneries, pigment
manufacturing and stainless steel welding is associated with the induction of lung cancer in
workers employed in these industries (3, 5-7). In US, an air quality survey indicated that
people in several residential areas are exposed to particulate airborne chromium at
concentrations exceeding 100 times the chronic toxicity benchmark (8). Therefore, in
addition to occupational exposure, environmental chromium is an emerging concern and is
associated with long-term carcinogenic effects of the lung. Even though several
epidemiological studies have demonstrated the carcinogenic potential of Cr(VI)
compounds, animal studies do not support this observation. Several groups have
established in various animal models including rat, mice, guinea pigs and rabbits that
exposure to Cr(VI) compounds demonstrated no significant increase in lung tumors with
respect to the untreated control (9-11). The problems associated with the development of
animal models to study Cr(VI)-induced carcinogenesis is poorly understood. Therefore,
lack of a good model becomes a major hindrance in studying the molecular mechanisms
involved in Cr(VI)-induced carcinogenesis. In this study, we developed an in vitro model
for studying the molecular mechanisms underlying Cr(VI)-induced malignant
transformation.
The carcinogenic potential of chromium is attributed to various factors including chemical
speciation, water solubility and intracellular reductive metabolism. Chromates with low
solubility are less carcinogenic as compared to soluble chromates (12). Cr(VI) does not
interact with the DNA directly. It has to be converted to Cr(III) inside the cell which then
intercalates with the DNA causing DNA strand breaks, DNA-protein cross-links and CrDNA adduct formation (13). In this process, ROS is generated that are believed to play an
important role in the cytotoxicity induced by Cr(VI) (14) by causing cell cycle arrest,
neoplastic transformation, and apoptosis induction (13, 15). It is well-established that
dysregulated apoptosis contributes to tumor promotion, autoimmune and
immunodeficiency diseases, and neurodegenerative disorders (16). Abnormal ROS
generation and apoptosis regulatory mechanisms have been considered as the most
important factors in neoplastic development in response to Cr(VI). Since human lung
cancer manifests mostly as epithelial cell derived carcinomas (13), we used normal human
lung epithelial Beas-2B cell-line and human lung cancer H460 cell-line for this study.
Since it is not known whether Cr(VI) can directly transform human lung epithelial cells, we
developed an in vitro model of Cr(VI)-induced lung carcinogenesis by subjecting the non-
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tumorigenic human lung epithelial Beas-2B cell line to long-term Cr(VI) exposure in vitro.
We also exposed human lung cancer epithelial H460 cells to Cr(VI) and compared the
effects in Beas-2B cells to this cell-type. We observed that long-term exposure of Cr(VI)
led to malignant transformation of the cells as exhibited by loss of contact inhibition,
increase in colony formation, cell proliferation, invasion and migration. In the previous
aims, we showed that ROS mediated Cr(VI)-induced apoptosis by the down-regulation of
the anti-apoptotic protein Bcl-2. NO inhibited Cr(VI)-induced apoptosis by nitrosylating
Bcl-2 protein that led to the stabilization and increased expression of Bcl-2 causing
inhibition of apoptosis. Cr(VI) transformed cells showed decreased ROS production and
apoptosis. They further demonstrated an increase in NO and inhibition of Bcl-2 downregulation verifying our earlier observations. The development of such an in vitro model
allows detailed examination of the molecular changes underlying Cr(VI)-induced
carcinogenesis in a system that is of clear relevance to human exposure and validates
human lung epithelial cells as a direct target for Cr(VI)-induced carcinogenesis.
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4.3. Materials and Methods
Chemicals and Reagents
Sodium dichromate (Na2Cr2O7.2H2O) [Cr(VI)], 6-Anilinoquinoline-5,8-quinone (LY83,583), Hydrogen peroxide (H2O2), NO donor sodium nitroprusside (SNP), NO inhibitors
aminoguanidine (AG) and 2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxy-3oxide (PTIO) were obtained from Sigma Chemical Inc. (St. Louis, MO). Mn(III)tetrakis (4benzoic acid) porphyrin (MnTBAP) was purchased from Calbiochem (La Jolla, CA), and
catalase was from Boehringer Mannheim (Indianapolis, IN). NO donor
dipropylenetriamine (DPTA) NONOate was from Alexis Biochemicals (San Diego, CA).
The oxidative probes, dichlorofluorescein diacetate (DCF-DA), dihydroethidium bromide
(DHE), diaminofluorescien diacetate (DAF-DA) and the apoptosis dye Hoechst 33342
were from Molecular Probes (Eugene, OR). Antibodies for Bcl-2 and peroxidase-labeled
secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). β-actin
antibody was from Sigma (St. Louis, MO).
Cell Culture
The normal bronchial epithelial Beas-2B cell line and human lung cancer epithelial H460
cell line were obtained from ATCC (Rockville, MD). Beas-2B cells were cultured in
DMEM media (Sigma, St. Louis, MO) containing 5% fetal bovine serum, 2 mM Lglutamine, 100 units/ml penicillin and 100 µg/ml streptomycin and H460 cells were
cultured in RPMI 1640 medium (Sigma, St. Louis, MO) containing 5% fetal bovine serum,
2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2
environment at 37ºC. Cells were passaged at preconfluent densities using a solution
containing 0.05% trypsin and 0.5 mM EDTA (Invitrogen).
Derivation of transformed cells
Beas-2B and H460 cells were exposed continuously to 5 µM Cr(VI) and incubated in a 5%
CO2 environment at 37ºC. Cells were passaged weekly at preconfluent densities using a
solution containing 0.05% trypsin and 0.5 mM EDTA (Invitrogen). Henceforth, Cr(VI)
exposed cells are designated as B-Cr and H-Cr cells to distinguish them from the parental
Beas-2B and H460 cells, respectively. Parallel cultures grown in Cr(VI) free medium
provided passage-matched controls. After 24 weeks of exposure, phenotypic changes were
observed in both B-Cr and H-Cr cells. The transformed cells were then grown in normal
media and their tumorigenic potential was assessed by various experiments, described
below.
Cyquant cell proliferation assay
Beas-2B, B-Cr, H460 and H-Cr cells were plated in a 96-well plate at a density of 1 × 104
in growth media and were incubated for 24 h. The growth media was changed with 100 µl
of 1X Cyquant dye binding solution (Invitrogen) and were incubated for 30-60 min at
37°C. The fluorescence intensity of each sample was measured at 485/535 nm.
Cell invasion and migration
In vitro invasion and migration was determined by a modified Boyden chamber assay using
cell culture inserts with a polycarbonate-filter coated with Matrigel (BD Biosciences, NJ)
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for invasion or control inserts for migration in a 24-well format. Briefly, 3 × 104 cells
(invasion) or 1.5 × 104 cells (migration) in 500 µl of serum-free media were added to the
inserts. The lower chambers were filled with 5% FBS in media. Chambers were incubated
at 37°C in a 5% CO2 atmosphere for 24 h for migration and 48 h for invasion. The noninvading or non-migrating cells were removed from the insides of the inserts by cotton
swabs. The cells that invaded the matrigel or migrated to the underside of the coated
membrane were fixed and stained with Diff-Quik fixative and stain. The cell nuclei stain
purple and the cytoplasm stains pink. The inserts were directly examined under a light
microscope and the number of cells migrated or invaded was counted.
Soft agar colony assay
Soft agar assays were performed as described previously with minor modifications (17).
Beas-2B, B-Cr, H460 and H-Cr cells (3 × 104 cells for each cell-type) were mixed with
tissue culture media containing 0.5 % agar to result in a final agar concentration of 0.33 %.
Cell suspension (1.5 ml) was immediately plated in 60 mm dishes coated with 7 ml/plate of
0.5 % agar in tissue culture media. After 2 weeks, the number of colonies per 3 x 104 cells
were counted under a light microscope.
Apoptosis Assay
After specific treatments, apoptosis was determined by incubating the cells with 10 µg/ml
Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the percentage of cells having
intensely condensed chromatin and/or fragmented nuclei by fluorescence microscopy
(Axiovert 100; Carl Zeiss) using Pixera software.
ROS and NO Detection
Intracellular peroxide, ·O2‾ and NO production were determined by spectrophotometry
using DCF-DA, DHE or DAF-DA fluorescence probes, respectively. Cells (1x106/ml)
were incubated with the fluoresecent probes (10 µM) for 30 min at 37ºC, after which they
were washed with PBS, and analyzed for DCF (494/519 nm), DHE (535/617 nm) or DAF
(488/ 538nm) fluorescence using FLUOstar OPTIMA (BMG Inc., Durham, NC).
Western Blotting
After specific treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl
(pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF,
100 mM PMSF, and a commercial protease inhibitor mixture (Roche) for 20 min on ice.
After insoluble debris was precipitated by centrifugation at 14,000 x g for 15 min at 4oC,
the supernatants were collected and assayed for protein content using BCA method (Pierce
Biotechnology, Rockford, IL). Equal amount of proteins per sample (15 µg) were resolved
on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto 0.45-µm nitrocellulose membrane (Pierce). The transferred membranes
were blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl pH 7.4, 125 mM
NaCl, 0.05% Tween-20) and incubated with the appropriate primary antibodies and
horseradish peroxidase-conjugated isotype-specific secondary antibodies. The immune
complexes were detected by chemiluminescence (Supersignal® West Pico, Pierce).
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4.4. Results
Cr(VI)-Induced Malignant Transformation of Normal Lung Epithelial Cells – Normal
human bronchial epithelial cells Beas-2B were continuously exposed to 5 µM Cr(VI) and
were passaged weekly. After 24 weeks of exposure, phenotypic differences were observed
between the Cr(VI)-treated and passage-matched control cells. The treated cells, designated
as B-Cr, were subsequently cultured in Cr(VI)-free medium and soon began to form cell
mounds, even when subconfluent, whereas mounding was not observed in passagematched control cells (Fig. 1). This mounding indicated loss of contact inhibition and was
the first indication of the transformation of Beas-2B cells. This was also observed in the
cancer cell line used. As expected, cell mounding was observed in passage-matched control
lung cancer epithelial H460 cells; however, treatment with Cr(VI) led to increased
malignant transformation of the H460 cells. Cr(VI) transformed cells were stained with
Hoechst stain to elucidate the colony formation clearly (Fig.1). As seen in the figure normal
Beas-2B cells undergo malignant transformation leading to colony formation and loss of
contact inhibition. Loss of contact inhibition is a characteristic in vitro feature of tumor
progression (18).
Confirmation of Cr(VI)-Induced Malignant Transformation – Soft agar colony formation
assay was performed to confirm Cr(VI)-induced malignant transformation (Fig. 2). Beas2B, B-Cr, H460 and H-Cr cells were subjected to colony formation by growing them on
agar plates as described in Materials and Methods to assess anchorage independent growth.
After 2 weeks, B-Cr cells showed a 4 fold increase in colony formation as compared to the
Beas-2B cells and H-Cr cells showed a 2 fold increase in colony formation as compared to
the H460 cells (Fig. 2, A and B). These experiments demonstrated significant colony
formation in Cr(VI) transformed cells, although very small, slowly growing colonies were
also formed by normal human lung epithelial Beas-2B cells. It was also observed that the
number of colonies formed by B-Cr cells were approximately equal to the number of
colonies formed by the passage controlled H460 cells, indicating the carcinogenic potential
of normal human lung epithelial cells, as H460 is a cancer cell-line.
Effect of Cr(VI)-Induced Malignant Transformation on Cellular Proliferation – We further
examined the proliferation of control and Cr(VI)-transformed lung epithelial cells in a
complete medium. The transformed B-Cr cells proliferated approximately twice as fast as
the control cells (Fig. 3), in keeping with their malignant behavior. Although H460 cells are
lung cancer epithelial cells, exposure to Cr(VI) transformed this cell-line, further making it
more malignant. H-Cr cells proliferated slightly faster than H460 cells. Overall, the
transformed cells showed rapid growth as compared to the original cell-lines.
Effect of Cr(VI)-Induced Malignant Transformation on Cellular Invasion and Migration –
Cr(VI) exposed cells were assessed in vitro for the potential to migrate through and invade
matrigel. The invasive and migratory properties of the transformed cells were compared to
the original cell-lines. B-Cr cells demonstrated approximately 4.5 fold increase in invasion
and nearly 4 fold increase in the migration rate as compared to passage-matched Beas-2B
cells (Fig. 4A). H-Cr cells demonstrated more than 5 fold increase in invasion and 4.5 fold
increase in the migration rate as compared to passage-matched H460 cells (Fig. 4A). This
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result indicated the aggressive and malignant nature of the Cr(VI) transformed cells.
Apoptosis Levels in Cr(VI) Transformed Cells – Dysregulation of apoptosis regulatory
mechanisms in response to Cr(VI) exposure has been implicated in Cr(VI)-induced
malignant transformation (19). Therefore, to study the mechanism involved in Cr(VI)
induced malignant transformation, we characterized the apoptotic response in transformed
cells as compared to normal cells. Cells were treated with different doses of Cr(VI) (0-100
µM), and apoptosis was determined after 12 h by Hoechst 33342 assay. Figs. 5, A and B,
show that Cr(VI) treatment caused a dose-dependent increase in cell apoptosis in Beas-2B
and H460 cells and, comparatively, B-Cr and H-Cr cells demonstrated reduced apoptosis.
This indicated that continuous exposure of Cr(VI) modifies cellular system such that the
damaged cells escape apoptosis and undergo malignant transformation.
Cellular ROS Levels in Cr(VI) Transformed Cells – As demonstrated in aim II, Cr(VI)
induced ROS production is involved in apoptosis induction. Since we observed a decrease
in apoptosis in Cr(VI) transformed cells, we quantified the ROS levels in these transformed
cells. When we treated B-Cr and H-Cr cells with Cr(VI), we observed that hydroperoxide
and ·O2‾ production was significantly reduced as compared to Beas-2B and H460 cells in a
dose-dependent manner, as indicated by the decrease in DCF and DHE fluorescence
intensity (Figs. 6, A-D). This observation was verified by treating cells with various ROS
modulators along with Cr(VI). ROS modulators showed significantly decreased ROS levels
in Cr(VI) transformed cells as compared to the passage-matched control cell-lines (Fig. 7,
A-D). This suggests that cells acquire apoptosis resistant phenotype by decreasing ROS
production that leads to decreased apoptosis in response to Cr(VI).
Cellular NO Levels in Cr(VI) Transformed Cells – We demonstrated in aim III that NO
inhibits Cr(VI)-induced apoptosis by nitrosylating and stabilizing Bcl-2 protein. Therefore,
NO regulates cellular events such that cells become resistant to apoptosis. NO mediated
regulation of Cr(VI)-induced apoptosis may be a key mechanism by which cells acquire
apoptosis resistant phenotype. To test this possibility we quantified the NO levels in Cr(VI)
transformed cells as compared to the passage-matched control cells. It was observed that
NO production induced in response to Cr(VI) in Beas-2B and H460 cells was further
increased significantly in B-Cr and H-Cr cells in a dose-dependent manner, as indicated by
the increase in DAF fluorescence intensity (Figs. 8, A and B). Further, NO modulation
studies confirmed this result (Fig. 8, C and D). This indicated that malignant transformation
involves increased NO production and thus confirmed our earlier study that NO exerts an
anti-apoptotic role in response to Cr(VI) exposure.
Bcl-2 Expression Levels in Cr(VI) Transformed Cells – The oncogenic potential of Bcl-2 is
well-established with its overexpression reported in various cancers including lung cancer
(20-24). In our earlier aims, we found that Bcl-2 is the key anti-apoptotic protein involved
in inhibiting Cr(VI)-induced apoptosis. Having demonstrated the important role of Bcl-2 in
Cr(VI)-induced apoptosis, we examined the potential modification of Bcl-2 expression in
Cr(VI) transformed cells. To provide a mechanistic insight into the dysregulation of
Cr(VI)-induced apoptosis, the expression level of Bcl-2 in response to Cr(VI) treatment
was determined in B-Cr and H-Cr cells as compared to Beas-2B and H460 cells by
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Western blot analysis. Figs. 9, A and B show that Bcl-2 is down-regulated in Beas-2B and
H460 cells, however this effect was reversed and Bcl-2 was stabilized in B-Cr and H-Cr
cells. This suggested that persistent and long-term exposure to Cr(VI) leads to the
stabilization and overexpression of the anti-apoptotic protein Bcl-2 that causes inhibition of
apoptosis and malignant transformation of the cells.
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4.5. Discussion
Cr(VI) is a known human carcinogen that induces lung cancer (3, 5-7). Several
epidemiological studies have demonstrated the carcinogenic potential of Cr(VI)
compounds. However, the mechanisms involved in Cr(VI) induced carcinogenesis are
poorly understood. One of the major hindrances is the lack of an appropriate model for
studying Cr(VI) induced malignant tranformation because exposure to Cr(VI) does not
induce lung tumor formation in animals (9-11). Since there is no direct evidence
demonstrating the carcinogenic potential of Cr(VI), we developed an in vitro model of
Cr(VI)-induced lung carcinogenesis by subjecting the non-tumorigenic human lung
epithelial Beas-2B cell line to long-term Cr(VI) exposure in vitro. In addition, we also
exposed human lung cancer epithelial H460 cells to Cr(VI) further transforming these cells
and compared the effects in Beas-2B cells to the control and transformed H460 cells to
validate our observations. We observed that long-term exposure of these cells to Cr(VI) led
to malignant transformation of the cells as observed by the loss of contact inhibition in
vitro of the non-tumorigenic human lung epithelial Beas-2B cell-line (Fig.1). This is an
exclusive property of cancer cells and demonstrates the malignant transformation of normal
cells in response to Cr(VI) exposure. B-Cr and H-Cr cells demonstrated anchorageindependent growth and increased colony formation in soft agar as compared to the
passage-matched original cell-line confirming the malignant potential of Cr(VI)
transformed cell-lines (Fig. 2). The number of colonies formed by B-Cr was comparable to
the number of colonies formed by H460 cells confirming the carcinogenic potential of
Cr(VI) transformed Beas-2B cells. Although Beas-2B cells are normal human bronchial
epithelium obtained from autopsy of non-cancerous individuals, they also developed
significantly less number of slow growing colonies. Beas-2B cells are widely reported to
possess mutated and non-functional p53 gene (tumor suppressor gene) (25, 26) and ATCC
product datasheet indicates that Beas-2B cell-line forms colonies in semisolid medium but
were non-tumorigenic in immunosuppressed mice. Therefore, the colony formation
observed in Beas-2B cells is due to inherent cell properties and not due to its tumorigenic
potential. Cr(VI) transformed cells demonstrated an increase in the proliferation, invasion
and migration rates as compared to the passage-matched control cells demonstrating their
aggressive and malignant behavior (Fig. 3 and 4).
We further characterized the mechanism involved in the malignant transformation of
normal lung epithelial cells in response to Cr(VI) exposure. We have earlier shown that
Cr(VI) induces apoptosis through the mitochondrial pathway and Bcl-2 plays an important
role in this system. ROS mediates Cr(VI)-induced apoptosis by the down-regulation of the
anti-apoptotic Bcl-2 protein and NO inhibited this effect by S-nitrosylating the protein that
led to the stabilization and increased expression of Bcl-2 causing inhibition of apoptosis.
Therefore, we tested the possibility of the involvement of this mechanism in Cr(VI)
induced malignant transformation. We observed that the transformed cells showed
decreased ROS production and increased NO production (Fig. 6, 7 and 8). Moreover, it was
observed that apoptosis was inhibited and Bcl-2 was up-regulated in the Cr(VI)
transformed cells (Fig. 5 and 9). These observations in the Cr(VI) transformed cells
confirmed our earlier studies and revealed one of the important mechanisms responsible for
Cr(VI)-induced malignant transformation. This study is important because it is the first, to
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our knowledge, description of Cr(VI)-induced malignant transformation of a human lung
epithelial cell-line analogous to a potential in vivo target cell population relevant to Cr(VI)induced carcinogenesis in humans. This study is also biologically significant, as there is
established epidemiologic evidence that human lung is a potential target of Cr(VI) inducedcarcinogenicity. More importantly, it provides a model in which the molecular and genetic
events associated with Cr(VI)-induced carcinogenesis in humans can be studied. Since
Cr(VI) is a paradigm of carcinogenic transition metals, the inferences from this study may
be broadly applied for studying molecular mechanisms associated with general metal
carcinogenesis.
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FIGURE 1. Cr(VI)-induced malignant transformation of normal human lung
epithelial cells. Normal human bronchial epithelial Beas-2B cells were exposed to 5 µM
Cr(VI) for 24 weeks. A, Passage-matched control Beas-2B and B-Cr cells stained with
Hoechst 33342 dye (top). Passage-matched control Beas-2B and B-Cr cells under light
microscope(bottom). B, Fluorescence micrographs of B-Cr cells after 24 weeks of Cr(VI)
exposure.
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FIGURE 2. Cr(VI)-induced malignant transformation assessed by Soft Agar colony
formation. A, Beas-2B, B-Cr, H460 and H-Cr cells (3 x 104 cells) were seeded on 0.5 %
agar plates and were incubated at 37oC in a 5% CO2 incubator. After 2 weeks, colonies
were scored under a light microscope. B, Representative micrographs of colonies formed
by Beas-2B, B-Cr, H460 and H-Cr cells in soft agar. Values are mean ± S.D. (n > 3). *, p <
0.05 versus the respective passage-matched control cell-line.
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FIGURE 3. Effect of Cr(VI)-induced malignant transformation on cellular
proliferation. Beas-2B, B-Cr, H460 and H-Cr cells were plated in a 96-well plate at a
density of 1 × 104 in growth media and were incubated for 24 h. The growth media was
changed with 100 µl of 1X Cyquant dye binding solution and were incubated for 30-60 min
at 37°C. The fluorescence intensity of each sample was measured at 485/535 nm. Values
are mean ± S.D. (n > 3). *, p < 0.05 versus the respective passage-matched control cellline.
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FIGURE 4. Effect of Cr(VI)-induced malignant transformation on cellular invasion
and migration. A and B, Beas-2B, B-Cr, H460 and H-Cr cells at a density of 3 × 104 or 1.5
× 104 cells/ml were added to inserts coated with matrigel (invasion) or control inserts
(migration), respectively. The inserts were incubated for 48 h for invasion assay and 24 h
for migration assay. Cells were counted under fluorescence microscope after staining and
the average number of cells was scored in each case. Values are mean ± S.D. (n > 3). *, p <
0.05 versus the respective passage-matched control cells. C, Representative micrographs of
cells stained for invasion.
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FIGURE 5. Apoptosis in Cr(VI) transformed cells. A and B, subconfluent (90%)
monolayers of Beas-2B, B-Cr, H460 and H-Cr cells were exposed to varying doses of
Cr(VI) (0-100 µM) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342
assay. Plots are mean ± S.D. (n = 4). *, p < 0.05 versus non-treated control.
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FIGURE 6. Cellular ROS levels in Cr(VI) transformed cells. A, B, C and D spectrophotometric measurements of DHE and DCF fluorescence intensities in Beas-2B,
B-Cr, H460 and H-Cr cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show
relative fluorescence intensity over non-treated control. Values are mean ± S.D. (n > 3). E,
F, G and H, Beas-2B, B-Cr, H460 and H-Cr cells were either left untreated or pretreated
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM) or H2O2 (0.1 mM)
for 0.5 h, followed by Cr(VI) treatment (20 µM) for 1 h . Plots show relative fluorescence
intensity over non-treated control. Values are mean ± S.D. (n > 3).

93

FIGURE 7. Effect of ROS modulators on Cr(VI) transformed cells. A, B, C and D spectrophotometric measurements of DHE and DCF fluorescence intensities in Beas-2B,
B-Cr, H460 and H-Cr cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show
relative fluorescence intensity over non-treated control. Values are mean ± S.D. (n > 3). E,
F, G and H, Beas-2B, B-Cr, H460 and H-Cr cells were either left untreated or pretreated
with MnTBAP (100 µM), catalase (10000 U/ml), LY-83,583 (10 µM) or H2O2 (0.1 mM)
for 0.5 h, followed by Cr(VI) treatment (20 µM) for 1 h . Plots show relative fluorescence
intensity over non-treated control. Values are mean ± S.D. (n > 3).
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FIGURE 8. Cellular NO levels in Cr(VI) transformed cells. A and B spectrophotometric measurement of DAF fluorescence in Beas-2B, B-Cr, H460 and H-Cr
cells. Cells were treated with Cr(VI) (0-100 µM) for 1 h. Plots show relative fluorescence
intensity over non-treated control. C and D, Beas-2B, B-Cr, H460 and H-Cr cells were
pretreated for 0.5 h with SNP (500 µg/ml), DPTA NONOate (400 µM), AG (300 µM), and
PTIO (300 µM). The cells were then treated with Cr(VI) (20 µM) for 1 h and were
analyzed for DAF fluorescence. Plots show relative fluorescence intensity over non-treated
control. Values are mean ± S.D. (n > 3).
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FIGURE 9. Bcl-2 expression in Cr(VI) transformed cells. A and B, Beas-2B, B-Cr, H460
and H-Cr cells were treated with Cr(VI) for 12 h, and cell lysates were prepared and
analyzed for Bcl-2 by Western blotting.
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OVERALL CONCLUSIONS

 Both extrinsic and intrinsic pathways of apoptosis are induced in human lung
epithelial cells in response to Cr(VI) exposure, with the mitochondrial pathway
being more dominant.
 Overexpression of the mitochondrial anti-apoptotic protein Bcl-2 significantly
inhibits Cr(VI)-induced apoptosis.
 ROS, specifically ·O2‾, is important in mediating apoptosis in response to Cr(VI)
exposure.
 Mitochondrion is the main source of ROS production during Cr(VI)-induced
apoptosis.
 ·O2‾ induces apoptotic cell death, at least in part, by inducing proteasomal
degradation of Bcl-2 protein in response to Cr(VI) exposure.
 NO plays an anti-apoptotic role in Cr(VI)-induced apoptosis.
 NO mediates its effect, at least in part, by the inhibition of proteasome-mediated
degradation of Bcl-2.
 The mechanism by which NO regulates Bcl-2 involves S-nitrosylation of the
protein, which was also observed under other stress conditions, including exposure
to death ligand and glutathione depletion.
 NO mediated ONOO¯ is the major reactive nitrogen species involved in SNitrosylation of Bcl-2 that prevents its downregulation via the ubiquitin-proteasome
pathway.
 Both Cys158 and Cys229 are involved in S-nitrosylation and ubiquitination of Bcl-2,
with Cys229 being the major site for nitrosylation.
 Chronic Cr(VI) exposure can induce malignant transformation of normal human
lung epithelial cells.
 The in vitro model of Cr(VI)-induced malignant transformation verified that the
molecular mechanisms recognized in our study are important in Cr(VI)-induced
carcinogenesis.
 Cr(VI)-induced malignant transformation of human lung epithelial cells is of clear
relevance to human exposure and validates human lung epithelial cells as a direct
target for Cr(VI)-induced carcinogenesis.
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